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ABSTRACT 
As members of the ribosomally synthesized and post-translationally modified peptide 
natural products (RiPPs), lanthipeptides possess myriad structural diversity and potential for 
discovery using genome-guided approaches. Biological activities of interest embedded within 
lanthipeptide structures include antimicrobial, antiviral, and morphogenetic functions. Continued 
discovery efforts seek to expand the characterized activities and structures of these compounds, 
as well as the enzymes that execute their biosynthesis. 
The contents of this thesis are focused on the discovery of lanthipeptides using a variety 
of methods. Chapters 2 and 4 demonstrate the application of heterologous expression of gene 
clusters to produce lanthipeptides. The resulting peptide structures and enzyme activities provide 
intriguing insights into diversity of biosynthetic approaches present in this class of compounds. 
Furthermore, the abundance of precursor peptides encoded in the lanthipeptide biosynthetic 
systems discussed in Chapters 2 and 4 offer examples of combinatorial biosynthesis and the 
tantalizing possibility to harness this attribute. In contrast, Chapter 3 provides a glimpse into the 
targeted screening of Actinobacteria for the production of lanthipeptides, which suggests 
additional structural diversity. The successful application of these methods increases the number 
of lanthipeptide compounds and systems, which ultimately allows for a deeper understanding of 
and appreciation for this class of natural products. 
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Chapter 1. Introduction 
 
1.1 Ribosomally synthesized and post-translationally modified peptide natural products 
(RiPPs) 
Natural products are a significant source of pharmaceutical compounds as well as tools to 
probe biological processes (1, 2). Recently, peptide natural products have attracted attention for 
the advantages they offer including high target selectivity and the potential to interact with 
targets with larger surface areas such as in protein-protein interactions. Despite these attractive 
features, several challenges remain including low metabolic stability (5). Natural products 
containing amide bonds can be stabilized by additional chemical groups that decorate the peptide 
scaffold (Figure 1.1). One set of compounds that exemplify this approach are ribosomally 
synthesized and post-translationally modified peptide natural products (RiPPs) which are a 
sprawling and growing class of compounds that can be subdivided based on their post-
translational modifications (6). In contrast to non-ribosomal peptide synthetases, the scaffold for 
the final compound of a RiPP is encoded within the biosynthetic gene cluster along with the 
modification machinery. Within the RiPP designation are lanthipeptides, which exhibit an array 
of structural features (Figure 1.1, 1.2) as well as biological activities, with the subset of 
lanthipeptides that exhibit antimicrobial activity termed lantibiotics. Their post-translational 
modifications are key to the activity of lanthipeptides, thus there is sustained interest in exploring 
their biosynthesis as well as discovering new lanthipeptides. 
Similar to other RiPPs, lanthipeptide biosynthesis is comprised of three parts: expression 
of the precursor peptide and protein genes, post-translational modification installation, and leader 
peptide removal (Figure 1.2).  First, both the synthetase(s) and substrate (generically termed 
LanA) genes are transcribed and translated. The latter comprises an N-terminal leader peptide 
and a C-terminal core peptide, which are delineated by a sometimes conserved cleavage motif. 
The synthase enzyme(s) then catalyze(s) the dehydration and cyclization of core peptide residues 
in the substrate to dehydro amino acids (abbreviated as Dha and Dhb) and methyl(lanthionine) 
residues, abbreviated as (Me)Lan (Figure 1.2, 1.3). Post-translational modifications aside from 
the thioether rings can also be installed, and finally proteolytic removal of the leader peptide 
yields the mature lanthipeptide. The ribosomal heritage of lanthipeptides offers an opportunity 
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for facile modifications of the final product scaffold via mutagenesis, and additional 
modifications increase the chemical diversity of lanthipeptides. 
 
 
 
 
 
 
 
Figure 1.1. Chemical linkages found in RiPP macrocycles. Representative substructures are drawn. Additional 
modifications found in lanthipeptides, and shared with other classes, are indicated with colored circles. Shared 
structures are not installed by the same enzymes. Some macrocycle linkages are not exclusive for representative 
compounds, for example, sactipeptides also contain thioether linkages. 
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In addition to the namesake (Me)Lan residues that are key to their bioactivity, 
lanthipeptides possess additional post-translational modifications (Figure 1.1). Unlike the 
(Me)Lan linkages, these modifications usually occur at a single residue in the peptide. 
Investigation into the activities of the enzymes responsible for these modifications suggests 
substrate tolerance at an amino acid level, and in some cases enzyme activity in the absence of 
leader peptide. Thus, there is interest in developing these enzymes as substrate-tolerant 
bioengineering tools. Continued efforts toward the discovery of new lanthipeptides have revealed 
new post-translational modifications as well as new activities of the resulting peptide products 
(7-9).  
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Figure 1.2. Lanthipeptide biosynthesis. (A) Lacticin 481 maturation shown in context of an outline of RiPP 
biosynthesis. (B) Structures of a variety of lanthipeptides. Lan shown in red, (Me)Lan in blue, and single residue 
post-translational modifications in chartreuse. 
α 
β 
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1.2 LanM proteins: structural and mechanistic insights 
 Lanthipeptides are divided into classes based on the bioinformatic annotation and 
mechanistic distinction of their synthases (Figure 1.3A). Compounds from class I are 
biosynthesized by a discrete LanB and LanC protein, class II are modified by a bifunctional 
LanM protein, class III by a trifunctional LanKC protein, and class IV by yet another 
trifunctional LanL enzyme (10). The LanB proteins in class I synthases are responsible for 
dehydration of the Ser and Thr residues within the LanA core peptide while the LanC cyclases 
catalyze the addition of the thiols of Cys residues onto the dehydro amino acids (Figure 1.3B, C). 
In comparison, the class II-IV synthetases rely on a single enzyme for both dehydration and 
cyclization activity. However, the class II-IV enzymes have distinct domains. The class II 
enzymes comprise an N-terminal dehydratase and C-terminal cyclase domain while class III and 
IV enzymes consist of a kinase, lyase and cyclase domain (Figure 1.3A). As a reflection of their 
annotated differences, the four classes of lanthipeptide synthases employ distinct strategies to 
affect the dehydration of core peptide residues (Figure 1.3B, C). The class I synthase NisB 
activates the hydroxyl of Ser and Thr residues by glutamylation, using aminoacylated glutamyl-
tRNA as the glutamyl source (11, 12). In contrast, class II-IV enzymes use nucleoside 
triphosphates to phosphorylate Ser and Thr residues, which upon phosphate elimination produce 
dehydro amino acids (10). 
Canonical LanM proteins are typically about 1,000 amino acids in length and can be 
divided into an N-terminal dehydratase domain and C-terminal cyclization domain (Figure 1.3A, 
1.4). These domain borders can be visualized in silico using Pfam’s Hidden Markov model 
(HMM)-based search, and the National Center for Biotechnology Information’s (NCBI’s) 
BLAST also outputs a cyclization domain annotation (13, 14). Alignment of characterized LanM 
proteins, which typically share around 30% identity, reveals the presence of conserved residues 
in both domains (10). Initial studies into the significance of these residues were carried out on 
the synthase LctM and necessitated reconstitution of its in vitro activity, which required both 
adenosine triphosphate (ATP) and Mg
2+
 (15). Subsequent mutations of conserved residues in the 
dehydratase domain of LctM resulted in mutant enzymes with decreased dehydration activity or 
that produced phosphorylated LctA. These observations suggested a mechanism in which net 
dehydration was achieved via addition of a phosphoryl group, from ATP, followed by phosphate 
elimination, with Mg
2+
 proposed to assist in elimination (Figure 1.3B) (16). Complementary 
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mutagenesis studies were undertaken for proposed Zn
2+
 coordinating residues (His725, Cys781, 
and Cys836) within the cyclization domain of LctM. Specifically, mutagenesis resulted in 
enzymes that were unable to cyclize the substrate, suggesting a thiol coordinating and activating 
role for zinc (Figure 1.4) (17). 
 
 
 
 
 
 
Figure 1.3. Lanthipeptide synthases and modifications. (A) Schematic of the domains of lanthipeptide synthases 
from each class. (B) Mechanism for dehydro amino acid formation. (C) Mechanism for thioether ring formation 
and resultant (Me)Lan stereochemistries. Figure adapted from (3). 
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These functional and structural predictions provided by the primary sequence and 
biochemical studies can be contextualized in the crystal structure of CylM. The CylM monomer 
consists of a dehydratase domain that resembles lipid kinases and which is attached to a C-
terminal cyclization domain which contains a coordinated zinc. In addition to substantiating the 
proximity of residues identified as conserved by alignment, co-crystal structures with adenosine 
monophosphate (AMP) identified residues within a nucleotide binding pocket, with Asp252, 
His254, Arg506, and Thr512 proposed as involved in phosphate elimination (18). Inactivation of 
elimination activity via mutations at these residues was demonstrated for LctM, ProcM, and 
CylM, with the former two demonstrating potential application as general kinases as a result of 
their substrate tolerance (Figure 1.4) (19, 20). Due to lack of co-crystallization with substrate, the 
contacts that the leader peptide makes with the enzyme and the trajectory of the core peptide 
during catalysis remain elusive. The bioinformatic and structural separation of the dehydratase 
and cyclase domains could be translated to functional decoupling of the dehydratase and cyclase 
domain activities (Figure 1.4). Separation of the dehydration and cyclization domains of several 
LanM enzymes including BovM, CylM, LctM, NukM, and ProcM yielded outcomes ranging 
from fully functional to completely inactive discrete domains (21-25). 
Studies employing time dependent assays, tandem mass spectrometry (MS), and selective 
Cys alkylation agents have provided some insight into the dehydration and cyclization reactions 
carried out by LanM enzymes (26). Initial studies employing high-resolution tandem MS and 
mutant LctM enzyme and HalM2 revealed distributive and an overall N- to C-terminal 
directional behavior for both enzymes (27). Subsequent semi-quantitative MS strategies have 
yielded higher resolution kinetic insight into the dehydration and cyclization reactions of wild 
type HalM2 and ProcM (28). The data substantiate the distributive behavior of these enzymes 
and provided evidence for alternating installation of dehydrated amino acids and thioether 
linkages with a general directionality, as opposed to full dehydration of the substrate followed by 
cyclization (28). Despite belonging to the same class of lanthipeptide synthetases, the overall 
directionality for ProcM is C- to N-terminal, which is opposite of that observed for HalM2. 
Furthermore, comparison of HalM2 and ProcM revealed substantial kinetic differences, with the 
latter exhibiting significantly slower rates of cyclization compared to the former (28). The slower 
rate of ProcM cyclization catalysis is juxtaposed with its ability to cyclize a plethora of natural 
substrates, which may be incompatible with high catalytic efficiency. 
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Inherent to the discussion of the enzymatically formed ring topologies are the 
stereochemistries of the α-carbon of the (Me)Lan rings (Figure 1.3C). Since dehydration and 
cyclization only involves the Ser or Thr sidechain and the thiol of Cys, the α-carbon of Cys 
remains untouched. Thus, two stereochemical outcomes are possible in the case of Lan, the 
2S,6R isomer designated as DL-Lan and the 2R,6R isomer designated as LL-Lan. The additional 
methyl group at the former β-carbon of Thr also yields two isomers for MeLan, 2S,3S,6R for DL-
MeLan and 2R,3R,6R for LL-MeLan (Figure 1.3C). The MeLan isomers 2S,3R,6R and 2R,3S,6R 
have not been found in lanthipeptides to date. Contrary to the DL-(Me)Lan configuration 
expected for all lanthipeptides, the thioether rings of the two peptides of the cytolysins were 
observed to have LL stereochemistry. Based on these observations as well as the sequence of the 
peptides it was hypothesized that the Dhx-Dhx-Xxx-Xxx-Cys motif was associated with the LL 
stereochemical outcome and was corroborated upon analysis of peptides bearing said motif (8, 
29, 30). 
 
 
 
 
Figure 1.4. LanM bioengineering. Fusing the leader peptide to its cognate synthetase yields the ConFusion 
enzyme (4). Mutation of conserved residues within substrate-tolerant LanM proteins results in monofunctional 
enzymes capable of phosphorylating or dehydrating a variety of substrate peptides. Peptides containing dehydro 
amino acids can also be produced by using a truncated LanM enzyme lacking the cyclization domain (∆cyc 
LanM). 
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In addition to the strides made in understanding canonical LanM catalysis, non-canonical 
LanM enzymes have emerged and been the subject of investigation. In these cases, the 
dehydratase domain of the LanM can be identified but conserved residues in the cyclization 
domain are missing. Intriguingly, the gene clusters encoding for these non-canonical LanMs also 
often encode for reductases, which were demonstrated to reduce select dehydro amino acids 
installed by the cognate LanM protein into D-amino acids (8, 31, 32). Understandably these 
bioinformatically distinguished LanM proteins have yielded appreciation for the diversity of 
genetic contexts and corresponding biosynthetic roles that these enzymes assume, including in 
non-lantibiotic gene clusters (33). 
 
1.3 In vivo and in vitro production of lanthipeptides 
 The approaches thus far reported for the production of lanthipeptides can be divided into 
two broad categories, in vivo or in vitro. The former can be further subdivided into strategies 
using the native organism or a heterologous host, and the latter into enzymatic or synthetic 
approaches (Figure 1.5). Reports of the development of genetic tools to activate gene clusters of 
interest followed by screening are limited, perhaps due to the genetic diversity of organisms that 
encode lanthipeptide gene clusters (34). In contrast, expression of gene clusters in heterologous 
hosts or reconstitution of enzyme activities in vitro has enjoyed widespread application. 
Complementary synthetic strategies have also been developed and have enabled access to 
additional chemical diversity. Most of the discussed strategies require leader peptide removal, 
which is discussed in further detail in section 1.4. 
The small sizes of lanthipeptide biosynthetic gene clusters facilitates their amplification 
and cloning into plasmids for heterologous expression. Production of individual peptides and 
proteins is undertaken using established methods for protein production. In order to access the 
modified peptide, the peptide and protein genes are simultaneously expressed in the host. 
Subsequent purification of the peptide is accomplished using a combination of affinity and high 
performance liquid chromatographies (35). Due to the relative brevity of most lanthipeptide 
biosynthetic pathways (two to three enzymes for installation of the thioether rings), careful 
verification and optimization of enzyme expression is feasible. Heterologous production of 
lanthipeptides has been demonstrated only in the cases of class I and II systems, although 
expression of unmodified peptides and biosynthetic proteins is regularly performed for 
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lanthipeptides from all four classes (10). Cases of insoluble enzymes and/or substrates appear to 
be limited and can usually be overcome by the use of fusion proteins (36, 37). In addition, the 
heterologous expression of lanthipeptide systems is compatible with other protein engineering 
technologies such as unnatural amino acid incorporation, which has provided access to 
lanthipeptide substrates with non-proteinogenic functional groups (38-41). Expression of active 
class II synthetase enzymes in E. coli has proved especially facile, as reflected in the large and 
continuously increasing reports of reconstituted class II systems (42). 
 
 
 
 
 
 
Although the heterologous production of peptides and proteins has been and continues to 
be fruitful, mechanistic information was limited through this approach. Thus, the in vitro 
reconstitution of lanthipeptide synthases was undertaken and has facilitated the study of not only 
the (Me)Lan-forming enzymes but also subsequent tailoring steps (12, 15, 43, 44). Detailed 
discussion of the resulting mechanistic insights can be found in section 1.3. Preparation for in 
vitro studies is procedurally similar to co-expression except that the LanA and synthase enzymes 
are expressed and purified separately (35). The demonstrated substrate tolerance of LanM 
Figure 1.5. Strategies for lanthipeptide production. The leader peptide is indicated in orange, which can be 
produced by a heterologous host. Also, core peptides can be synthetically prepared and ligated to leader peptides 
in preparation for post-translational modification by a synthetase. 
11 
 
proteins, in part due to the modularity of the peptide scaffold, enabled in vitro biosynthetic 
modification of synthetic peptides. In these approaches synthetically prepared core peptide is 
ligated to a heterologously prepared leader peptide and exposed to the cognate synthase (Figure 
1.5). Ligation is accomplished using expressed protein ligation or copper-catalyzed azide-alkyne 
cycloadditions (45, 46). The semi-synthetic core peptides can be prepared to serve as isotopically 
labelled substrates for mechanistic studies or post-translationally modified products that exhibit 
increased antimicrobial activity (47-49). Reliance on the leader peptide was more recently 
diminished by its incorporation into the synthase, thereby obviating the need for leader peptide 
ligation by producing a constitutively active enzyme (Figure 1.3) (4, 50). Thus far, in vitro 
preparation of lanthipeptide derivatives has heavily focused on the two class II synthetases LctM 
and ProcM. These studies highlight the impressive substrate tolerance and bioengineered 
capabilities of the class II biosynthetic machinery. 
 Lactocin S is the first lantibiotic to be synthesized on solid-support, and since then, the 
total synthesis on solid-support of several lantibiotics has been completed (51-54). Although 
procedures for coupling the peptide backbones are well established, installation of the thioether 
macrocycles in lanthipeptides presented a challenge. The strategy that was adopted involves 
preparation of synthetic (Me)Lan residues bearing orthogonal protecting groups on a set of 
amines and carboxylates, which allow for controlled and ordered macrocyclization and linear 
peptide elongation events. The selective coupling of one set of the (Me)Lan carboxylates and 
amines to the peptide chain is followed by deprotection of the second carboxylate of the 
(Me)Lan residue and coupling to form the thioether ring. Deprotection of the last amine allows 
for continued elongation of the peptide backbone (51-54). The ensuing discussions are focused 
on structure and activity relationships, with mechanistic observations discussed in section 1.3. 
Relatively minor structural changes to the thioether linkages in lacticin 3147 β result in 
analogues with retained but diminished antimicrobial activity. For example, a desmethyl variant 
of lacticin 3147 β, wherein the two MeLan rings are replaced with Lan rings, exhibited 
synergistic antimicrobial activity with its α component but 100-fold less than the natural 
compound (55). Progressive changes in the thioether rings of lacticin 3147 β by substitution of 
the sulfur atom with a pair of double bonded carbon atoms or oxygen atom resulted in 
compounds with diminished antimicrobial activities compared to the natural lantibiotic (56, 57). 
Similarly, synthetically accessed cytolysin and lacticin 481 diastereomers exhibited decreased 
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antimicrobial activity compared to their respective natural compounds, highlighting the 
importance of stereochemistry for activity (53, 54). However, some conservative perturbations 
are tolerated, for instance substitution of the A ring of lactocin S with a methylene group resulted 
in a variant with antimicrobial activity comparable to the natural lantibiotic (58). 
 
1.4 Diversity, function, and removal of lanthipeptide leader peptides 
The leader peptide is hypothesized to serve two functions during the biosynthetic 
maturation of lanthipeptides, the first is coordination of the biosynthetic events and the second is 
immunity. Succinct demonstration of the latter is provided by a qualitative decrease in the 
antimicrobial activity of full length, modified nisin as well as haloduracin α in combination with 
haloduracin β (59, 60). Illustrations of the former function are captured by the two proposed 
models of the role of the leader peptide during lanthipeptide post-translational modification: 
activation of synthase activity upon binding of leader peptide or ensnaring of an active enzyme 
subpopulation by the leader peptide (61). One observation that distinguishes between the two 
possibilities is that presentation of the LctA core peptide, in the absence of the LctA leader 
peptide to its corresponding synthetase LctM results in LctA core peptide modification (62). This 
outcome is incompatible with a strict requirement of the leader peptide for synthetase activation 
and is consistent with a limited portion of LctM enzymes being present in a conformationally 
active state. Although modification of the core peptide can be observed in the absence of leader 
peptide, core peptide alone is not sufficient for efficient modification. Indeed, subsequent 
iterations of employing LctM as a substrate tolerant catalyst fused the LctA leader peptide to the 
synthetase resulting in a constitutively active fusion enzyme termed ConFusion (Figure 1.4) (4). 
The improvement in LanA processing efficiency that the leader peptide provides is partially 
clarified by studies that quantify leader and core peptide binding to a synthetase. Specifically, the 
HalA2 leader peptide dissociation constant from HalM2 is significantly smaller than that of 
HalA2 core peptide. The contribution to binding that the HalA2 leader peptide offers is captured 
in the dissociation constants of full length HalA2 from HalM2 and the core peptide from 
ConFusion HalM2, which are similar to that of HalM2 for leader peptide alone (63). Perhaps the 
most revealing illustration of leader peptide importance is provided by studies into the 
processing of separated leader and core peptides. Systems in which the LctA leader peptide is 
separated from the core peptide exhibit differences in directionality and fidelity of modification 
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compared to the wild type system as well as an overall decrease in reaction rates, which explains 
the decreased efficiency of the ConFusion system for example (25). 
 
 
 
 
 
Leader peptides from the different lanthipeptide classes exhibit diversity in their 
sequence and length, which parallels the diversity of the corresponding biosynthetic enzymes. In 
general, leader peptides from all lanthipeptide classes range from approximately 23 to 59 amino 
acids in length and have been proposed to adopt a helical conformation in select solvents and 
upon synthase binding (35, 64-66). In order to numerically discriminate between the leader and 
core peptides, the first, N-terminal residue of the core peptide is numbered “1” while the last C-
terminal residue of the leader peptide is numbered “−1” with preceding N-terminal leader 
peptide residues bearing lower (i.e. more negative) numbers. Lanthipeptides from clusters in 
which more than two LanA substrates are encoded feature conserved leader peptides for all of 
the substrates (67-69), presumably due to convergence towards or duplication of a leader peptide 
sequence that efficiently interacts with its cognate synthase. In contrast, two-component 
lantibiotic systems, in which activity of an enzyme requires localization to a specific substrate, 
generally feature distinct leader peptides for the LanA1 and A2 precursor peptides. An exception 
is cytolysin for which the leader peptides of the two substrates have high homology. In some 
Figure 1.6. Leader peptide alignment and removal. Alignments of portions of the leader peptide of select 
members from each class of lanthipeptide. Conserved motifs are highlighted in red (A) for class I, blue (B) for 
class II and green (C) for class III. Reproduced from ref. (3). 
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cases, lanthipeptide leader peptides are bioinformatically annotated as nitrile hydratase-like 
(NHLP) or Nif11-like (68, 70), although the evolutionary underpinnings for this observation 
have not been elucidated. However other lanthipeptide leader peptides are not typically 
bioinformatically annotated, but do feature conserved amino acid sequence motifs that can be 
discerned in some cases (Figure 1.6) and include FNLD in class I leader peptides (71), GG/GA at 
the juncture between leader and core in class II leader peptides, and ILD/ELQ at the N-terminus 
of class III leader peptides (12, 66). 
Although important for the post-translational modification of the precursor peptide, the 
leader peptide must be removed for manifestation of full activity (Figure 1.2A). In class I 
lanthipeptide systems, proteolysis of the leader peptide is completed by a LanP enzyme, which 
bears similarity to subtilisin-like serine proteases (44, 72). Leader peptide removal in class II 
systems is carried out by the bifunctional enzyme generally termed LanT, which also exports the 
final product into the extracellular space (73). LanT proteins are bioinformatically and 
structurally annotated as containing an N-terminal Cys protease domain, a transmembrane 
domain, and a C-terminal ATP-binding cassette (74). The apparent modularity could be 
translated into in vitro reconstitution of the Cys protease domain for the class II lantibiotic 
transporter LctT (75). Surprisingly, despite their encoding within genomes of Gram-positive 
bacteria, heterologous reconstitution of LanT activities in the Gram-negative heterologous host 
E. coli has proved successful in the case of the two-component lantibiotic lichenicidin (76), and 
as discussed in Chapter 2, may be generalizable. Preliminary support for this idea is presented by 
BovT150M, a fusion protein that combines the protease activity of the LanT BovT with the 
cognate synthetase BovM. BovT150M exhibited in vivo and in vitro activity in that it was able to 
modify and remove the leader peptide of its endogenous substrate BovA as well as a chimeric 
peptide consisting of the BovA leader and suicin core peptide (77). Lastly, leader peptide 
removal for class III lanthipeptides has only been characterized for the case of FlaP. This prolyl 
oligopeptidase exhibits some selectivity for dehydrated and cyclized peptide over unmodified, 
linear peptide (36). Finally, an appreciable number of lanthipeptides lack any of the 
aforementioned dedicated proteases encoded within their gene cluster, as exemplified by the 
microbisporicin gene cluster (78). In these cases it is hypothesized that other endogenous 
proteases encoded elsewhere in the genome affect leader peptide removal. Based on the limited 
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reports of leader peptide removal, the genetically encoded approaches to leader peptide removal 
could be as diverse as the strategies to dehydrate and cyclize the core peptides. 
Intriguingly, additional N-terminal processing of the core peptide is observed in the cases 
of the two-component lantibiotics cytolysin, haloduracin, and lichenicidin (76, 79, 80). In the 
former case, haloduracin β isolated from the producing organism (Bacillus halodurans C-125) 
was observed to have a mass less than that calculated from proteolysis at the canonical GG/GA 
cleavage site. Furthermore, these additional amino acids from modified haloduracin β cut at the 
predicted site were removed upon exposure to B. halodurans C-125 culture supernatant. The 
responsible protease was not readily annotated by examination of the haloduracin gene cluster, 
since no additional proteases or protease domain containing enzymes (aside from HalT) were 
encoded in the gene cluster. In contrast, the lichenicidin gene cluster encodes both LicT and LicP 
for initial cleavage at the GG/GA motif and subsequent removal of a NDVNPE sequence, 
respectively (76, 81). Although the protein machinery for leader peptide removal is not fully 
conserved among the different classes of lanthipeptides, some dedicated lanthipeptide leader 
removal enzymes have demonstrated substrate tolerance. Aside from the NDVNPE recognition 
motif, LicP exhibits impressive substrate tolerance and was employed to efficiently proteolyze a 
variety of both linear and modified substrates (81). 
Leader peptide removal in vitro is typically affected by commercial proteases, 
incorporation of a chemically cleavable moiety, or more recently by reconstitution of the activity 
of the endogenous protease. Although all of these strategies have been successfully employed, 
doing so requires optimization for each system. In the case of commercial proteases, the protease 
recognition site is usually not present in the core peptide such that the leader peptide is 
completely removed from the core peptide. However, incorporation of the commercial protease 
recognition site sometimes disrupts LanA processing, resulting in incomplete peptide 
modification (71, 82, 83). Disruption to processing can sometimes be minimized by 
incorporating non-amino acid functionalities between the leader and core peptides such as a 
base-labile ester linkage or a photocleavable aryl moiety (39, 84). Indeed, both approaches were 
executed to produce lacticin 481, but the requirement of unnatural amino acid incorporation or 
synthesis and ligation of the leader and core peptides can lower yields. In contrast, the alternative 
approach of reconstituting the activity of the LanT protease domain has only been demonstrated 
in three cases (32, 75, 77) and efforts to reconstitute the activities of protease domain truncants 
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of LanT proteins have produced inconsistent results. Furthermore, the lack of an encoded leader 
peptide removal enzyme in many lanthipeptide gene clusters precludes reconstitution of their 
activity. Conceivably, a suite of substrate-tolerant lanthipeptide proteases could provide the 
benefits of robust, traceless leader peptide removal without perturbation of the LanA sequence. 
Efforts to identify leader peptide contacts with the lanthipeptide biosynthetic proteins 
were hampered by lack of synthase structures and a bioinformatically discernable domain. 
However, the co-crystallization of the leader peptide of NisA with NisB revealed interaction of 
the former with a winged helix-turn-helix motif structure within the latter (12). Notably, 
analogous structures, designated the RiPP precursor peptide recognition element (RRE), were 
identified from a collection of RiPP post-translational modification enzymes which included 
NisB (85). Additionally, the identified RRE appears distributed in over half of the representative 
RiPP gene clusters surveyed, further implicating leader peptide recognition during biosynthesis 
in RiPPs other than lanthipeptides. Despite repeated illustration of leader peptide importance, 
several lanthipeptide biosynthetic enzymes that introduce diversity beyond thioether crosslinks 
function in the absence of leader peptide (44, 86-88). This observation prompts caution against 
overstating the role of the leader peptide for biosynthesis, but does not detract from its 
established functions. 
 
1.5 Lipid targets of lanthipeptides 
 Although lanthipeptides exhibit a variety of activities, definitive targets have been 
proposed only in the case of lantibiotics. Lipid II has been demonstrated and extrapolated as a 
target for most lantibiotics, while phosphatidylethanolamine is the proposed target of 
cinnamycin-like compounds (89, 90). Although extensive mutagenesis studies have been carried 
out on lantibiotics (91), fewer studies on the secondary structure of the peptides have been 
conducted. Furthermore, there have been only two reported structures of lanthipeptides in 
complex with their corresponding lipid target, which are discussed in more detail below. The 
involvement of secondary structure in target binding gained from the two available peptide-lipid 
complex structures and the roles of specific amino acids in these contexts bear some implications 
for the discovery of new lanthipeptides. 
Many class I lantibiotics characterized to date exert their antimicrobial activity by 
binding the cell wall intermediate lipid II, and the low occurrence of resistance against 
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lantibiotics has been ascribed to their targeting this late stage cell wall biosynthesis intermediate 
(92). An NMR structure of the complex between nisin and lipid II revealed encapsulation of the 
pyrophosphate group of lipid II within a cage-like structure formed by the A and B rings of nisin 
(93) while the remaining hinge and C-terminal portion of the molecule are implicated in 
membrane insertion and pore formation. Although the hinge region does not directly contact 
lipid II, its functional importance was evidenced by mutagenesis of this region, which resulted in 
peptides with reduced antimicrobial activity relative to wild type nisin (94). Interestingly, 
biosynthesis of the lipid II binding nisin A/B ring is exclusively carried out by class I enzymes 
(34). 
In addition to the lipid II binding nisin A/B ring motif, many lantibiotics biosynthesized 
by class II (LanM) enzymes feature another hypothesized lipid II binding motif found in the 
exemplary lantibiotic mersacidin. A six-membered thioether ring, usually the third ring of these 
peptides, is implicated in interacting with lipid II (95). Although NMR investigation of 
mersacidin in the presence of lipid II did not reveal direct contacts, significant conformational 
changes in the former were observed upon addition of the latter (96). Within the proposed lipid II 
binding motif of mersacidin is an indispensable Glu residue, which upon mutation results in a 
loss of activity (97). The proposed lipid II binding portion of mersacidin is also observed in class 
II, two-component lantibiotics. In these cases, the mersacidin-like lipid II binding portion is 
found in the α peptide, which presents a relatively more globular structure compared to the 
corresponding β peptides (Figure 1.2B). The model of α peptide-mediated recognition and 
binding to lipid II followed by β peptide-mediated pore-formation is supported by sequential 
addition and washing studies of lacticin 3147 and observed inhibition of transglycosylation and 
membrane disruption that haloduracin causes (60, 98-100). Lastly, the NMR structure of the 
lantibiotic cinnamycin in complex with lysophosphatidylethanolamine (PE) also highlights the 
importance of the (Me)Lan rings (101). Specifically, the ethanolamine headgroup of PE was 
nestled in a pocket formed by the B and C rings of the highly crosslinked and globular 
cinnamycin structure (Figure 1.2B). Paralleling the biosynthesis of the A/B ring motif of class I 
lantibiotics, the installation of the mersacidin-like lipid II binding motif appears to be 
monopolized by class II synthetases. Genome guided discovery (using either the LanA or M 
sequences) have routinely produced two-component lantibiotics featuring the mersacidin-like 
lipid II binding motif (42). 
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 Lanthipeptides that do not exhibit antimicrobial activity do exhibit other activities 
including morphogenetic (102), antiallodynic (103), antiviral (7), and antifungal (104). However, 
definitive evidence for the targets of these peptides has not been presented. In addition, the 
continued discovery of new lanthipeptides which bear few sequence similarities to already 
characterized peptides presents a scenario in which attempts to extrapolate activity based on 
primary structure alone are difficult (31, 32). Lastly, the activities (physiological and otherwise) 
for a handful of other lanthipeptides (prochlorosins and venezuelins) remain unknown (37, 67). 
Given the characterized and hypothesized activities of lanthipeptides, it is tempting to speculate 
that the targets awaiting elucidation are cell wall or membrane associated components. However, 
in the absence of thorough screening efforts, the targets and cellular effects of the compounds 
will remain unknown. Although amino acid sequence conservation provides some reassurance 
for and indication of biological activity, the continued application of genome mining in pursuit 
of unusual lanthipeptide scaffolds leaves in its wake the non-trivial tasks of screening for activity 
and target identification. 
 
1.6 In silico lanthipeptide discovery 
Preliminary genome mining efforts for new lanthipeptides relied on manual querying of 
genomic databases with a sequence of interest (105). The two commonly surveyed databases are 
maintained by NCBI and the Department of Energy (Joint Genome Institute). Although the 
former boasts an exhaustive collection of genomes and encompasses the sequences found in 
Integrated Microbial Genomes & Microbiomes (IMG/M), the latter provides a more 
straightforward means of accessing and assessing potential gene clusters. Following the input of 
a lanthipeptide protein or peptide sequence of interest, the outputs of each program were 
manually surveyed and curated for “unusual” features in an iterative manner (the total or curated 
outputs were used as new query sequences) (106, 107). This approach is reliant on the user’s 
assessment and thus depended on the user’s familiarity with lanthipeptide literature. The ensuing 
sections highlight notable features of bioinformatics programs, challenges associated with 
genome mining operations, and projected trends for the resultant data. Several recent reviews 
offer comprehensive cataloging and discussion of available software (106, 108). 
Due to the relatively small size of the open reading frames that often encode for RiPP 
precursor peptides, several recent programs offer improved sensitivity for their detection (109). 
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Alternative to the protein query strategy, specific organism genomes can be queried for a variety 
of natural product gene clusters by employing programs such as the antibiotics and Secondary 
Metabolites Analysis Shell (antiSMASH), which provides a pan-natural product assessment of 
the biosynthetic potential encoded in a particular genome (110). In conjunction with the influx of 
information, effective appreciation of the data necessitates an intuitive graphical user interface 
that allows for meaningful and customizable visualization of the large amounts of information. In 
contrast to the list-based output offered by NCBI’s BLAST and antiSMASH, Cytoscape provides 
a network visualization that can be rearranged to reflect user-specified parameters such as the 
numerical quantification of similarity (111). Integration of output sequence information and 
attendant information is exemplified by output from the Enzyme Function Initiative (EFI), 
although this platform is not geared towards natural products per se (112, 113). A more relevant 
illustration is the arrangement of analyzed sequences into gene cluster families, from which a 
thorough overview of quantifiable correlations for each gene cluster can be gained (114). 
Despite advances in computational applications which brought about newfound, 
systematic appreciation for the diversity of lanthipeptides and RiPPs in general (115), 
advancements in discovery continue to rely on rate limiting wet lab empiricism. Furthermore, the 
current functionality offered by existing in silico tools, with respect to new structure elucidation, 
can be achieved with additional time and application of preexisting methods. For example, the 
structural prediction capabilities of antiSMASH are currently limited, but continued support and 
expansion should improve accuracy (116). The current state of these programs does not detract 
from the systematic documentation they have provided or from their future utility. Lastly, the 
current carefully curated storehouses of published information do not enable facile, 
downloadable access to sequences and coupling to previously published data. The lack of 
centralized repository and standardization of information storage rendered transmission of gene 
cluster information suboptimal. 
The repository Minimal Information about a Biosynthetic Gene cluster (MIBiG) hints at 
future trends towards a single platform that integrates the outputs of all of the platforms 
discussed above while requiring a single input. Certainly the call for standardization of 
nomenclature as well as the results of genome mining efforts reflect the popularity of and 
dedication to natural products research (61, 117). MIBiG attempts to address standardization, but 
currently relies on voluntary inputs, which may not be sufficiently compelling incentive for 
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participation. Providing access to the sequences in a standard format that is linked to relevant, 
published literature would allow users to build, integrate, and customize networks that address 
their research priorities. Standardizing data will not only facilitate gene cluster dissemination, but 
also indirectly refine a user’s ability to generate structural hypotheses. An inherent difficulty in 
the discussion of these in silico tools is their structural prediction utility in the case of gene 
clusters that bear little similarity to characterized systems, at minimum they provide a means to 
assess perceived structural novelty. It is also foreseeable that the categorized data could feed 
future forays into automated synthetic biology. 
The subsequent chapters describe my genome-guided contributions to the discovery of 
new lanthipeptides from a variety of microorganisms. Rather than the established method of 
screening physical samples for biological activities, a genomics approach was adopted, in which 
gene clusters of interest were identified in silico and the products elicited and characterized 
(118). The contents of this thesis relate examples of the latter approach. Specifically, Chapter 2 
describes the in silico identification and characterization of a collection of lanthipeptides that are 
produced by an example of a combinatorial biosynthetic system. Similarly, Chapter 3 presents an 
example of employing genetic information to guide rapid identification of lanthipeptides from 
Actinobacteria. Chapter 4 details ongoing efforts to characterize new peptides from a 
combination of RiPP genetic heritages. In this vein, Chapter 5 discusses initial efforts to 
characterize the mechanism of catalysis of small LanB (sLanB) enzymes as well as the final 
product from a sLanB-rich gene cluster. 
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Chapter 2. Production of lanthipeptides from the anaerobe Ruminococcus flavefaciens FD-
1 in Escherichia coli 
 
2.1 Introduction 
The human microbiome has received much attention in recent years for its connection to 
human health (1-3). Increasingly, the mutualistic relationship between the microbiome and host 
has been demonstrated (4-7). One of the beneficial roles of the gut microbiota of a healthy 
individual is believed to be the resistance that is provided against colonization by pathogens (8). 
Similarly, the microbiota of livestock is critical for animal health, and a better understanding of 
the mechanisms that confer pathogen resistance in this setting is desired. Ruminant animals such 
as cattle and sheep have a symbiotic relationship with ruminal microorganisms that can degrade 
cellulose and/or hemicellulose (9, 10). Among the bacteria with cellulose activity in the rumen 
are the anaerobic ruminococci (11). Some  Ruminococcus  strains have been reported to produce 
bacteriocins (12-16), a class of ribosomally produced antimicrobial compounds that may be 
important for maintaining a niche in the competitive microbial environment of the rumen as well 
as in the human gastrointestinal tract (17). Ruminococcus  flavefaciens FD-1 has a particularly 
high cellulolytic activity (18). It has not been reported to produce any antimicrobial peptides, but 
its genome was recently sequenced (19), providing a view of the genetic capability to produce 
such compounds. Here we show that its genome encodes an unusual group of lanthipeptides that 
are composed of four highly conserved copies of a peptide that likely binds lipid II and a diverse 
set of eight additional peptides, some of which act synergistically with the lipid II-binding 
peptide. The possible functional implications of the system in the context of the rumen 
environment are discussed in this Chapter.  
As mentioned in Chapter 1, lanthipeptides that display antibacterial activity are called 
lantibiotics, and interest in these compounds has stemmed from their potent antibacterial activity 
and low propensity for the development of resistance (20). Although the prospects of RiPP 
production in anaerobic organisms has been highlighted (21), relatively few such compounds 
produced by the genus Ruminococcus have been reported thus far (14, 22, 23). We designated 
the lanthipeptide biosynthetic gene cluster in R. flavefaciens FD-1 flv (Figure 2.1A). Compared 
to known lanthipeptide biosynthetic gene clusters, the flv cluster possesses unusual 
characteristics that drew our attention. The cluster encodes twelve putative lanA genes and two 
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putative lanM genes (Figure 2.1A). The large number of substrates is reminiscent of the 
prochlorosin-like systems (24, 25) and the presence of two LanM synthetases resembles two-
component lantibiotic systems such as lacticin 3147 and haloduracin (26, 27). As discussed in 
Chapter 1, most of the two-component lanthipeptides investigated to date consist of a lipid II-
binding α-peptide and a β-peptide that acts synergistically to affect pore formation via a poorly 
defined mechanism (28-32). The gene clusters for two-component lantibiotics usually encode a 
single copy of an α and a β-peptide, and hence the twelve FlvA peptides encoded within the flv 
gene cluster are unprecedented. In light of these unusual characteristics, we set out to obtain the 
modified FlvA peptides. Systematic production of these peptides facilitated their structural 
characterization and bioactivity analysis. 
 
2.2 Results 
2.2.1 Bioinformatic analysis of the FlvA substrates 
Inspection of the FlvA amino acid sequences revealed that four out of the twelve FlvA 
peptides possessed nearly identical amino acid sequences, with a single and two amino acid 
differences in the leader and core peptide, respectively (Figure 2.1B). Querying the non-
redundant protein database from the NCBI using the BLAST (33) with the core peptides from 
this nearly identical set of FlvA peptides returned the LicA1 peptide sequence (Figure 2.1C) (28, 
34-36). The modified LicA1 core peptide forms the α-peptide of the two-component lantibiotic 
lichenicidin. An alignment of the lichenicidin peptides and all of the FlvA peptides using the 
alignment program Clustal Omega (37) indicated that the latter could be roughly divided into a 
set of putative α and β precursor peptides (Figure 2.1C, D). The four nearly identical FlvA 
peptides (Figure 2.1B) make up the putative α-peptides and were designated FlvA1.x (where x = 
a-d), whereas the remaining eight FlvA peptides were hypothesized to be the corresponding β-
peptides and were designated FlvA2.x (where x = a-h). Whereas the FlvA1.x core peptide amino 
acid sequences resemble that of lichenicidin α, the core peptides of FlvA2.x exhibited more 
limited sequence similarity with lichenicidin β, although some of the Ser, Thr, and Cys residues 
in the C-termini were similarly positioned (Figure 2.1D). In general, the core peptides of the 
FlvA peptides are longer than those of the previously characterized α- and β-peptides. 
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Figure 2.1. Comparison of the flv system with known two-component lantibiotics. All alignments were performed 
using Clustal Omega. (A) The flv biosynthetic cluster encoded within the genome of R. flavefaciens FD-1. (B) 
Alignment of the full length FlvA peptides. The Glu at which endoproteinase Glu-C cleaves in each of the modified 
FlvA2.x peptides is shown in red. An arrow indicates the predicted endogenous FlvT cleavage site in the FlvA  
35 
 
Figure 2.1. (cont.) 
peptides. (C) Alignment of the FlvA1.a core peptide with previously reported α peptides of two-component 
lantibiotics. Dehydratable residues in the core peptides are highlighted in red and cysteine residues are highlighted in 
blue. The reported ring topology of lichenicidin is indicated above the sequence, and the proposed ring topology for 
the modified FlvA1 peptide is shown below the sequence. Hal denotes the locus for haloduracin, Ltn denotes the 
locus for lacticin 3147, and Lic the locus for lichenicidin. The conserved lipid II binding motif is indicated with a 
dotted line. (D) Alignment of the FlvA2.x peptides with reported β peptides of two-component lantibiotics. The 
fully conserved Pro is indicated with an asterisk. 
 
 
Further comparison of the FlvA peptides with other two-component lantibiotics revealed 
additional shared and unusual features. The FlvA1.a peptide has Ser20 and Cys30 positioned to 
form a putative lipid II binding motif (Figure 2.1C, underlined) discussed in Section 1.5 that is 
found in the lantibiotics mersacidin, lacticin 481, and nukacin ISK-1 (38-41) and in the α-peptide 
of two-component lantibiotics (28, 29, 34, 42).  However, compared to the other α-peptides, the 
FlvA1.x peptides contain more Cys residues in the core peptide (Figure 2.1C). The involvement 
of these Cys residues in thioether rings or disulfide bridges could endow the FlvA1.a peptide 
with increased stability, which may be important in the ruminal environment. Similar to the 
FlvA1.x peptides, many of the FlvA2.x core peptides (c-e, g, and h) also have additional Ser and 
Thr residues compared to other two-component β-peptides (Figure 2.1D). Notably, some of these 
residues form a putative Dhx-Dhx-Xxx-Xxx-Cys motif (where Dhx = Dha or Dhb and Xxx = 
any amino acid), which has been shown in some lanthipeptides to result in MeLan rings with LL 
stereochemistry (43-45). Corollary to the structural diversity of the FlvA2.x peptides would be a 
high substrate tolerance of the FlvM enzyme(s) responsible for installing the (Me)Lan rings. 
 
2.2.2 Attempted detection of modified FlvA production in R. flavefaciens FD-1 
Liquid cultures of anaerobically grown R. flavefaciens FD-1 were desalted and analyzed 
for the presence of FlvA peptides. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) analysis did not provide clear indication of masses 
corresponding to putative peptide products of the flv cluster. In alternative attempts to elicit 
peptide production, R. flavefaciens FD-1 and Ruminococcus albus 7 were co-cultured as well as 
grown in proximity to one another on solid media, an approach that has been successful for other 
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genera (46, 47). However, no new ions with m/z > 2000 could be observed by MALDI-TOF MS. 
These observations are representative of a commonly encountered hurdle in natural product 
research: the environmental triggers for expression of biosynthetic genes are generally poorly 
understood and often cannot be replicated in the laboratory (48, 49). The inability to detect 
potential products of the flv cluster prompted consideration of alternate strategies to produce and 
assess the products generated from the flv genes. 
 
2.2.3 Heterologous production of modified FlvA peptides 
To access the products of the Flv system, a validated heterologous production strategy 
using Escherichia coli was employed. This approach has been successfully applied to the 
production of several lantibiotics and involves the co-expression of a LanA peptide and cognate 
LanM enzyme in E. coli, which typically results in full post-translational modification of the 
peptide. The modified full length LanA peptide is then purified from E. coli and the leader 
peptide is removed in vitro using a variety of proteolytic strategies as discussed in Section 1.4 
(36, 43, 50-56). The sequence similarity of FlvM1 with characterized two-component LanM1 
enzymes is greater than the similarity of the latter enzymes with FlvM2. Thus, we hypothesized 
that FlvM1 was responsible for the modification of the putative FlvA1.x peptides and FlvM2 for 
the FlvA2.x peptides. To probe this hypothesis, we undertook pilot co-expression studies of an 
arbitrarily chosen peptide FlvA2.g with either FlvM1 or FlvM2. 
Figure 2.2. Modification of the FlvA peptides as observed by MALDI-TOF MS analysis. Modification of the FlvA 
peptides was observed as a loss of an integer number of 18 Da from the calculated, unmodified peptide mass. (A) In 
vitro modification of FlvA1.a by FlvM1. The red spectrum was observed upon exposure of FlvA1.a to FlvM1,  
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Figure 2.2. (cont.) 
whereas the black spectrum was observed in the absence of FlvM1. FlvA1.a six-fold dehydrated, calculated average 
[M+H]
+
 mass: 9832.74 m/z, observed average mass: 9833.65 m/z. FlvA1.a unmodified, calculated average [M+H]
+
 
mass: 9941.07 m/z, observed average mass: 9937.60 m/z. For FlvA1.a and FlvM1 heterologous co-expression, see 
Figure 2.3B. (B) In vivo modification of heterologously expressed FlvA2.b peptide (for the other FlvA2.x peptides, 
see Figure 2.4). FlvA2.b six-fold dehydrated, calculated average [M+H]
+
 mass: 8463.51 m/z, observed mass: 
8463.42 m/z. * Denotes ions with masses that correspond to gluconoylated starting material or product (57). 
 
 
Co-expression of FlvA2.g with FlvM2 resulted in dehydrated peptides whereas co-expression of 
FlvA2.g with FlvM1 yielded no dehydration as shown by the corresponding MALDI-TOF MS 
spectra (Figure 2.3A). Further experiments with all of the FlvA2.x peptides showed they were 
also dehydrated upon co-expression with FlvM2 in E. coli. Similarly, FlvA1.a was dehydrated 
upon co-expression with FlvM1 (Figure 2.3B). Identical results were obtained in vitro with 
enzymes and substrates that were expressed as His6-tagged fusion proteins and purified by 
immobilized affinity chromatography (IMAC, e.g. Figure 2.2A).  In all cases the number of 
dehydrations was observed to be less than the total number of Ser and Thr residues within the 
core peptide (Table 2.1, Figure 2.2B, Figure 2.4), but Ser and Thr residues that escape 
dehydration are not unusual in lanthipeptides (58) including the lichenicidins (35, 36). 
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Figure 2.3. (A) Co-expression of FlvA2.g with FlvM1 and FlvM2. The observed major dehydration product is 
indicated above each peak. Co-expression of FlvA2.g with FlvM2, but not FlvM1 resulted in modified peptide. The 
red spectrum was observed upon co-expression of FlvA2.g with FlvM1; the black spectrum was observed upon co-
expression of FlvA2.g with FlvM2. FlvA2.g unmodified, calculated (calc.) average (avg.) [M+H]
+
 mass: 9213.4 
m/z, observed (obsv.) avg. mass: 9214.6 m/z. FlvA2.g seven-fold dehydrated, calc. avg. [M+H]
+
 mass: 9087.3, obsv. 
avg. mass: 9088.9 m/z. (B) MALDI-TOF-MS spectra of full length FlvA1.a after co-expression with FlvM1. 
FlvA1.a six-fold dehydrated, calc. avg. [M+H]
+
 m/z: 9832.97, obsv. avg. m/z: 9832.63. 
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Table 2.1. Extent of dehydrations observed after co-expression of FlvA2.x with FlvM2 and 
FlvA1.a with FlvM1. The yields obtained for the core portion of the modified FlvA peptides 
range from 100-800 µg of purified peptide from 2 L of E. coli culture, depending on the method 
of removal of the leader peptide. 
Substrate Major product Number of Ser 
and Thr in the 
core peptide 
Number of Cys 
in the core 
peptide 
Lan MeLan 
FlvA2.a −7 H2O 8 1 DL - 
FlvA2.b −6 H2O 9 3 - DL 
FlvA2.c −5 H2O 10 4 LL DL 
FlvA2.d −7 H2O 9 5 DL, LL DL 
FlvA2.e −7 H2O 10 4 LL DL 
FlvA2.f −4 H2O 5 2 - DL 
FlvA2.g −7 H2O 9 4 LL DL 
FlvA2.h −7 H2O 10 4 DL, LL DL 
      
FlvA1.a −6 H2O 8 6 DL DL 
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Figure 2.4. (cont.) 
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Figure 2.4. MALDI-TOF-MS spectra of full length FlvA2.x peptides following co-expression with FlvM2 (panels 
A, C, E, G, I, K, M, O). The corresponding FlvA2.x fragments formed upon Glu-C digestion and RP-HPLC 
purification are shown in panels B, D, F, H, J, L, N, P. The arrow indicates the position at which endoproteinase 
Glu-C cleaved. * Denotes ions with masses that correspond to gluconoylated starting material or product. The 
observed major dehydration product is indicated above each peak. (A, B) FlvA2.a full length, 7-fold dehydrated, 
calc. avg. [M+H]
+
 m/z: 8156.33, obsv.: 8157.87. Glu-C fragment calc. [M+H]
+
 avg. m/z: 4080.91, obsv.: 4080.58. 
(C, D) FlvA2.b 6-fold dehydrated full length, calc. avg. [M+H]
+
 m/z: 8463.51 m/z, obsv.: 8463.42. Glu-C fragment 
calc. avg. [M+H]
+
 m/z: 3700.34, obsv.: 3700.29. (E, F) FlvA2.c full length, 5-fold dehydrated, calc. avg. [M+H]
+
 
m/z: 9048.18, obsv.: 9049.10. Glu-C fragment calc. avg. [M+H]
+
 m/z: 4295.96, obsv.: 4295.16 m/z. (G, H) FlvA2.d 
full length, 7-fold dehydrated, calc. avg. [M+H]
+
 m/z: 8217.13, obsv.: 8217.97. Glu-C fragment calc. avg. [M+H]
+
 
m/z: 3767.45, obsv.: 3767.00. (I, J) FlvA2.e full length, 7-fold dehydrated, calc. avg. [M+H]
+
: 9107.32, obsv.: 
9108.08 m/z. Glu-C fragment calc. avg. [M+H]
+
: 4195.97, obsv.: 4195.46 m/z. (K, L) FlvA2.f full length, 4-fold  
Figure 2.4. (cont.) 
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Figure 2.4. (cont.) 
dehydrated, calc. avg. [M+H]
+
 m/z: 7970.05, obsv.: 7970.78 m/z. Glu-C fragment calc. avg. [M+H]
+
 m/z: 4458.30, 
obsv.: 4458.79 m/z. (M, N) FlvA2.g full length, 7-fold dehydrated, calc. avg. [M+H]
+
 m/z: 9087.29, obsv.: 9087.93 
m/z. Glu-C fragment calc. avg. [M+H]
+
 m/z: 4248.00, obsv.: 4248.33 m/z. (O, P) FlvA2.h full length, 7-fold 
dehydrated, calc. avg. [M+H]
+
 m/z: 8382.40, obsv.: 8383.19 m/z. Glu-C fragment calc. avg. [M+H]
+
 m/z: 4482.17, 
obsv.: 4482.77 m/z. The “…” preceding each Glu-C fragment corresponds to the amino acid sequence 
(GSSHHHHHHSQDP) arising from translation of plasmid RSFDuet-1 at the start codon of MCS1. 
 
 
2.2.4 FlvM1 is selective for FlvA1 and FlvM2 is selective for the FlvA2 peptides 
To assess the substrate tolerance of FlvM1, FlvA2.a and FlvA2.g were also incubated in 
vitro with FlvM1 under identical conditions. Analysis of the assay revealed little to no 
modification of either peptide by FlvM1 (Figure 2.5). Similarly, FlvM2 was unable to modify 
FlvA1.a to any appreciable extent when exposed to the peptide in vitro under the standard 
reaction conditions (Figure 2.5). The inability of FlvM1 to modify FlvA2.a and FlvA2.g and 
FlvM2 to modify FlvA1.a suggests a high degree of substrate selectivity that is probably 
governed by recognition of the different leader peptides (Figure 2.1B) (59, 60). 
 
2.2.5 Partial FlvA2.x leader peptide removal and structural analysis 
The alignment of the amino acid sequences of the FlvA peptides shows a conserved 
GA/GG motif located in the middle of the peptides (Figure 2.1B). Based on previous studies of 
other class II lanthipeptides, this motif likely marks the boundary between the FlvA leader and 
core peptides (61). Usually, leader peptides ending in the GA/GG motif are removed by the Cys 
protease domain of LanT transporters (62), and indeed such a protein is present in the gene 
cluster (FlvT, Figure 2.1A). Evidence that the GA/GG sequence is indeed the cleavage motif for 
the FlvA peptides was provided by co-expression of FlvT with FlvM2 and FlvA2.g in E. coli. 
The supernatant of the co-expression was analyzed by MALDI-TOF MS, which resulted in 
detection of masses corresponding to cleavage of modified FlvA2.g after the GA sequence (see 
Section 2.2.6). These masses were not observed in the culture co-expressing only FlvM2 and 
FlvA2.g. This observation is consistent with the previously reported removal of the leader 
peptide of modified LicA2 upon expression of the lic gene cluster, which contains licT, in E. coli 
(36). Although the use of FlvT confirmed the predicted leader peptide cleavage site, this strategy 
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unfortunately did not yield sufficient quantities of the Flv and -peptides for structure 
determination, in part because of the difficulty associated with purifying the desired, modified 
peptide from partially dehydrated peptides that were also secreted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. FlvM1 specifically modifies FlvA1 and FlvM2 modifies FlvA2. * Denotes ions with masses that 
correspond to gluconoylated starting material or product (57). (A) In vitro modification of FlvA2.a by FlvM2 
(black), but not FlvM1 (red). FlvA2.a unmodified, calc. avg. [M+H]
+
 m/z: 8282.4, obsv.: 8282.2. FlvA2.a 7-fold 
dehydrated, calc. avg. [M+H]
+
 m/z: 8156.3, obsv.: 8157.9. (B) In vitro modification of FlvA2.g by FlvM2 (black), 
but not FlvM1 (red). FlvA2.g unmodified, calc. avg. [M+H]
+
 m/z: 9213.4, obsv.: 9214.6. FlvA2.g 7-fold dehydrated, 
calc. avg. [M+H]
+
 m/z: 9087.3, obsv.: 9088.9. (C) In vitro modification of FlvA1.a by FlvM1 (red), but not FlvM2  
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Figure 2.5. (cont.) 
(black). FlvA1.a unmodified, calc. avg. [M+H]
+
 m/z: 9941.1, obsv.: 9944.2. FlvA1.a 6-fold dehydrated, calc. avg. 
[M+H]
+
 m/z: 9833.0, obsv.: 9833.7. 
 
 
We therefore turned towards in vitro removal of the putative leader peptides from the 
His6-tagged FlvA2.x peptides after co-expression with FlvM2 and purification by IMAC. The 
purified peptides were first subjected to proteolysis by endoproteinase Glu-C. Although FlvA2.f-
2.h have Glu residues within their core peptides, appreciable proteolysis at these sites was not 
observed, probably because they are protected by the post-translational modifications. Instead, 
treatment with Glu-C resulted primarily in fragments arising from proteolysis within the leader 
peptide sequence, specifically at Glu−5 for FlvA2.a, Glu−6 for FlvA2.b through FlvA2.e and 
FlvA2.g, Glu−7 for FlvA2.h, and Glu−10 for FlvA2.f (for sequences, see Figure 2.1B). The Glu-
C-generated C-terminal fragments of the modified FlvA2.x peptides were purified by reversed-
phase high performance liquid chromatography (RP-HPLC) and analyzed by electrospray 
ionization tandem mass spectrometry (ESI-MS/MS) (e.g. Figure 2.6A). 
 
Figure 2.6. Structural analysis of the FlvM2-modified FlvA2.b. (A) Tandem mass spectrum of the modified 
FlvA2.b peptide after treatment with the endoprotease Glu-C. [M+H]
+
 denotes the peak corresponding to the 
protonated, monoisotopic parent mass. Fragment ions were not observed at the C-terminus of the peptide. For 
tandem mass spectra of the remaining FlvA peptides, see Figure 2.7. (B) GC/MS, selected ion monitoring at 379 Da, 
indicating the presence of MeLan. The identity of the eluting material was confirmed by co-elution with an authentic 
MeLan standard (Figure 2.8B). 
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A lack of fragmentation was observed in the C-termini of all of the modified FlvA2.x 
peptides analyzed, suggesting the presence of thioether rings (Figure 2.6A and 2.7). ESI-MS/MS 
analysis of modified FlvA1.a also indicated the absence of fragmentation in the C-terminus of 
the peptide, consistent with cyclization in this region of the peptide (Figure 2.7). To confirm the 
presence of (Me)Lan residues within the FlvM-modified FlvA1.a and FlvA2.x peptides, the 
peptides were hydrolyzed and the resulting residues were derivatized to the corresponding 
pentafluoropropionamide methyl esters. These volatile derivatives were then separated by chiral 
gas chromatography monitored by mass spectrometry (GC/MS), which confirmed that the 
modified FlvA1.a and FlvA2.x peptides indeed contained (Me)Lan residues (Figure 2.6B and 
Figure 2.8). The stereochemistry of the observed (Me)Lan residues was determined by using 
synthetic standards with known stereochemistries (63), and is listed in Table 2.1. As anticipated 
based on previous predictions (43), peptides containing a Dhx-Dhx-Xxx-Xxx-Cys motif resulted 
in LL-Lan whereas all other Lan and MeLan residues had the DL stereochemistry. 
 The possibility of incomplete cyclization was assessed by iodoacetamide (IAA) assays;  
iodoacetamide selectively alkylates free Cys residues and not thioethers. For all FlvM-modified 
peptides except FlvA1.a, treatment with IAA did not result in appreciable formation of adducts, 
which is indicative of complete cyclization; di-alkylation was observed with FlvM1-modified 
FlvA1.a (Figure 2.9C). Based on the fragmentation pattern (Figure 2.9D) and the alignment with 
other -peptides (Figure 2.1C), the di-alkylation product most likely involves alkylation at Cys8 
and Cys29. Two non-cyclized Cys are also present in haloduracin but the Cys residues 
involved do not align with those of Flv.a. The two free Cys residues in modified FlvA1.a 
presented the possibility of a disulfide bond in the structure of mature FlvAα.a. The 
antimicrobial activity of some lantibiotics has been reported to depend on the presence of such 
disulfide bonds (53, 64-66). Modified FlvA1.a was therefore incubated with oxidized and 
reduced glutathione in an attempt to oxidatively fold the peptide (67). However, the peptide 
remained reduced under these conditions, as observed by ESI-MS, suggesting that unlike 
lantibiotics that contain disulfide bonds, the two Cys in modified FlvA1.a are not in a 
conformation in which they readily form a disulfide bond (51, 54). We cannot rule out that 
disulfide bond formation needs to occur prior to (Me)Lan installation. 
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Figure 2.7. (cont.) 
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Figure 2.7. Tandem MS spectra of the FlvM modified FlvA peptides. [M+H]
+
 denotes the protonated, monoisotopic 
mass of the parent peak. The dehydration pattern supported by the tandem MS data is indicated. For regions in 
which the dehydration pattern is ambiguous, the number of dehydrations supported by the data is indicated with the 
total possible number of dehydrations in parentheses. For example, “1(2) dehydrated” means one out of two of the 
residues for the particular region of peptide were dehydrated. (A) FlvA2.a, (B) FlvA2.b, (C) FlvA2.c, (D) FlvA2.d, 
(E) FlvA2.e, (F) FlvA2.f, (G) FlvA2.g, (H) FlvA2.h, and (I) FlvA1.a. 
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Figure 2.8. GC/MS, selected ion monitoring (SIM) at 365 Da and 379 Da of the FlvM modified FlvA peptide 
fragments obtained by treatment with Glu-C, indicating the presence and stereochemistry of Me(Lan) residues. The 
stereochemistry of the (Me)Lan residues was confirmed by co-elution with authentic standards, (A) FlvA2.a. (B) 
FlvA2.b. (C-E) FlvA2.c. (F-H) FlvA2.d. (I-K) FlvA2.e. (L) FlvA2.f. (M-O) FlvA2.g. (P-R) FlvA2.h. (S, T) FlvA1.a. 
Foreground plots are of the sample while background plots are of sample mixed with standard. (i) SIM at 365 Da of 
the sample (Lan), (ii) SIM at 379 Da of the sample (MeLan), (iii) SIM at 379 Da of the sample mixed with DL- 
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Figure 2.8. (cont.) 
MeLan standard, (iv) SIM at 365 Da of the sample mixed with DL-Lan standard, (v) SIM at 365 Da of the sample 
mixed with LL-Lan standard. When no data is shown for Lan or MeLan, it indicates that the sample did not contain 
the residue. 
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Figure 2.9. (A) Bioactivity of FlvA peptides on Ruminococcus albus 7. Very similar activity was also observed with 
Ruminococcus flavefaciens C94. (B) Chymotrypsin treatment of modified FlvA1.a. The observed major peak 
corresponded to six-fold dehydrated FlvA1.a, calc. avg. [M+H]
+
 m/z: 4060.80, obsv.: 4060.68. The “…” before and 
after the amino acid sequence represents the omitted portion of the leader and core peptides, respectively 
GSSHHHHHHSQDPMNKNPIYRSEEEAKDIACGNVAAELDENSQALDAI and CTYTVE-CSKTCNK. (C) 
Iodoacetamide (IAA) treatment of FlvA1.a. The number of alkylation adducts is indicated above each peak, 
resulting in an increase of 57 Da. The red spectrum was observed upon exposure to iodoacetamide, whereas the 
black spectrum was observed in the absence of iodoacetamide. FlvA1.a six-fold dehydrated calc. avg. [M+H]
+
 m/z: 
4060.80, obsv.: 4059.02, obsv. mono-alkylated avg. mass: 4115.81 m/z, and obsv. di-alkylated avg. mass: 4172.75 
m/z. (D) Tandem MS spectrum of alkylated FlvA1.a. [M+H]
+
 denotes the protonated, monoisotopic mass of the 
parent peak. The alkylation pattern supported by the tandem MS data is indicated. (E) Modification and proteolysis 
of FlvA1.a. The black spectrum was observed upon co-expression of FlvA1.a(A−1insE) and FlvM1. The red 
spectrum was observed upon exposure of the modified FlvA1.a(A−1insE) peptide to Glu-C. FlvA1.a(A−1insE) six-
fold dehydrated calc. avg. [M+H]
+
 m/z: 9962.09, obsv.: 9962.42. FlvAα.a calc. avg. [M+H]+ m/z: 4304.07, obsv.:  
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Figure 2.9. (cont.) 
4303.29. (F) Bioactivity of ∆2-Flvα.a, Flvα.a, and Flvβ.b. (G) Aminopeptidase treatment of modified FlvA2.f 
resulting in +7Flvβ.f. The red spectrum was observed upon treatment of the modified FlvA2.f Glu-C fragment with 
aminopeptidase, whereas the black spectrum was observed in the absence of aminopeptidase. The observed major 
peak corresponds to 4-fold dehydrated FlvA2.f, calc. avg. [M+H]
+
 m/z: 4179.92, obsv.: 4180.98. The “…” 
preceding the amino acid sequence represents the omitted portion of the leader peptide that was removed using Glu-
C GSSHHHHHHSQDPMEKMNNIAGITPENELDEMF. (H) Co-expression of FlvA2.g, FlvM2, and FlvT. The red 
spectrum was observed from the supernatant of E. coli cells in which FlvA2.g, FlvM2, and FlvT were co-expressed, 
whereas the black spectrum was observed from the supernatant of the FlvA2.g and FlvM2 co-expression. The 
observed major peak corresponded to seven-fold dehydrated FlvA2.g, calc. avg. [M+H]
+
 mass: 3818.53 m/z, obsv. 
avg. mass: 3819.04 m/z. The “…” represents the omitted portion of the leader peptide GSSHHHHHHSQDP 
MNNNNFDMEKFKKLAAIVSEGEIDEMLDETT. 
 
 
2.2.6 FlvT proteolyzes and exports the FlvA2.x peptides and dehydrated LicA2 
Although insufficient quantities of isolable core peptide resulted from co-expression of 
FlvT with the FlvM2 and FlvA2.g (Figure 2.9H), the ability of FlvT to process the other FlvA2.x 
peptides remained unclear. Thus, the remaining FlvM2 and A2.x pairs were co-expressed with 
FlvT and in almost all cases, partially and fully dehydrated Flv2.x peptides were detected in the 
supernatant of the co-expression cultures (Figure 2.10). Notably, no fully modified peptide was 
observed in the co-expression culture of FlvA2.a. Additionally, co-expression of FlvT with 
LicA2 and LicM2 resulted in detection of dehydrated LicA2 in the supernatant of the expressing 
E. coli (Figure 2.10H). In contrast, FlvT co-expressed with FlvM1 and FlvA1.a did not result in 
detectable amounts of modified FlvA1.a. However, attempts to reconstitute the in vitro 
proteolytic activity of the Cys protease domain of FlvT (His6-FlvT151) were unsuccessful 
despite soluble expression of the truncated protein. 
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Figure 2.10. Modified core peptides observed in the supernatants of FlvT co-expression cultures. The masses of the 
labeled peaks corresponded to (A) two-fold dehydrated FlvA2.a, calc. avg. [M+H]
+
 m/z: 3783.6, obsv.: 3781.8, (B) 
six-fold dehydrated FlvA2.b, calc. avg. [M+H]
+
 m/z: 3255.8, obsv.: 3255.4, (C) five-fold dehydrated FlvA2.c, calc. 
avg. [M+H]
+
 m/z: 3866.5, obsv.: 3865.6, (D) seven-fold dehydrated FlvA2.d, calc. avg. [M+H]
+
 m/z: 3310.4, obsv.: 
3311.0, (E) three-fold dehydrated FlvA2.f, calc. avg. [M+H]
+
 m/z: 3554.3, obsv.: 3553.9, (F) seven-fold dehydrated 
FlvA2.g, calc. avg. [M+H]
+
 m/z: 3818.5, obsv.: 3818.1, (G) seven-fold dehydrated FlvA2.h, calc. avg. [M+H]
+
 m/z: 
3954.6, obsv.: 3956.0, and (H) 12-fold dehydrated LicA2, calc. avg. [M+H]
+
 m/z: 3690.2, obsv.: 3689.7. 
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2.2.7 Proteolytic removal of the remaining portion of the FlvA2.x leader peptides 
Complete removal of the leader peptide was challenging as introduction of artificial 
protease cleavage sites resulted in either incomplete modification by the FlvM enzymes, 
incomplete proteolysis because of the post-translational modifications near the cleavage site, or 
cleavage in the core peptides, which are problems that have been previously observed for other 
lanthipeptides (55, 68, 69). We therefore resorted to treating the Glu-C-generated FlvA2.x 
peptide fragments with aminopeptidase (70-72). It was anticipated that the proteolytic activity of 
aminopeptidase would terminate upon encountering the dehydrated residues featured at or near 
the predicted N-termini of most of the FlvA2.x peptides (Figure 2.12). MALDI-TOF-MS 
analysis of aminopeptidase reactions indicated that for FlvA2.b, the predicted native product was 
formed. For FlvA2.c, FlvA2.e, and FlvA2.g, aminopeptidase removed all remaining residues of 
the leader peptides as well as the predicted first residue of the core peptides, resulting in N-
terminal lanthionines. We term these products -Flvc, -Flve, and -Flvg. For FlvA2.d 
and FlvA2.h, the aminopeptidase treatment left two amino acids of the leader peptide on the final 
products, likely because of the high Gly content at the junction between the core and leader 
peptides, making these peptides less efficient substrates for aminopeptidase (73). We term these 
products Flvd and Flvh. For FlvA2.a, three residues remained after aminopeptidase 
treatment, resulting in +3Flv.a. Finally, in the case of FlvA2.f, seven residues from the leader 
peptide remained after aminopeptidase treatment (Figure 2.9G; Flvf). 
This sequential digestion approach works reasonably well when the N-terminus of the 
lanthipeptide is blocked by post-translational modifications, but if the N-terminus is a linear 
sequence as predicted for the product of FlvA1.a, the method does not work. Instead, removal of 
the FlvA1.a leader peptide was achieved via a single step proteolysis using chymotrypsin (Figure 
2.9B). Assuming that the GA/GG sequence marks the end of the leader peptide, chymotrypsin 
cleaves after Trp2 in the core peptide of FlvM1-modified FlvA1.a, and therefore the resulting 
peptide was designated -Flvα.a. In an effort to avoid removal of the two N-terminal amino 
acid residues of the FlvA1.a core peptide, a mutant FlvA1.a peptide with Glu inserted before the 
first residue of the core peptide was generated (termed FlvA1.a(A−1insE)), and co-expressed 
with FlvM1. Doing so resulted in six-fold dehydrated FlvA1.a(A−1insE), and treatment of this 
mutant peptide with Glu-C yielded the desired Flvα.a (Figure 2.9E). 
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2.2.8 Antimicrobial activity of the modified FlvA core peptides 
The peptides produced by in vitro leader peptide removal were purified by RP-HPLC, 
and the modified FlvA peptides were first assayed for antimicrobial activity against the 
lantibiotic-sensitive, aerobic microorganism Micrococcus luteus DSM 1790. In an agar diffusion 
test, -Flvβ.c and -Flvβ.e exhibited antimicrobial activity that was not synergistically 
enhanced by Flvα.a (Figure 2.11). In contrast, combinations of Flvβ.b or -Flvβ.g with 
Flvα.a displayed the synergistic antimicrobial activity that is characteristic of two-
component lantibiotics. A comparable level of synergistic, antimicrobial activity was also 
observed for a combination of Flvα.a and Flvβ.b (Figure 2.9F), suggesting that the removal of 
the additional two amino acids at the N-terminus of Flvα.a is not detrimental for bioactivity. 
Since we could obtain considerably larger quantities of Flvα.a, this peptide was used for all 
subsequent bioassays. -Flvβ.g also displayed activity by itself that was lower than that 
observed when spotted with Flvα.a. The remainder of the Flvβ-peptides (+3Flv.a, Flvd, 
Flvf, and Flvh) did not display antimicrobial activity, whether tested separately or in 
combination with Flvα.a (Figure 2.11). Enhanced activity beyond what was observed in 
pairwise combination was also not detected by combining all peptides. In light of their 
antimicrobial activity, Flvα.a, β.b, β.c, β.e, and β.g were designated flavecins. 
M. luteus is often used as an indicator strain to test for antimicrobial activity of lipid II-
targeting peptides such as two-component lantibiotics, but it is not a rumen bacterium. To 
investigate the activity of the peptides against bacteria that would be more relevant in the 
ruminal context, the flavecins were assayed against Ruminococcus albus 7 and R. flavefaciens 
C94 under anaerobic conditions. Interestingly, very similar patterns of activity were observed 
with Flvα.a, Flvβ.b, and -Flvβ.e (Figure 2.9A). As with M. luteus, the activity was weak, 
suggesting that these organisms are not the intended target of these compounds. Alternatively, 
the weak antimicrobial activity exhibited by the flavecins may suggest that these peptides 
mediate more subtle microbial interactions (74).  
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Figure 2.11. Bioassay of FlvM-modified FlvA core peptides against M. luteus DSM 1790. The modified 2-Flv.a 
peptide was assayed at a concentration of 1 mM and the Flv.x peptides were assayed at a concentration of 0.5 mM. 
A volume of 1 µL was used for spots consisting of a single peptide while 0.5 µL of each solution was used for spots 
combining two peptides; nisin was assayed using 0.2 µL of a 100 µM solution. 
 
 
2.3 Discussion 
The sequence similarity of LanM enzymes was used to survey genomes for unusual class 
II lanthipeptide biosynthetic systems, which resulted in the identification of the novel flv gene 
cluster in R. flavefaciens FD-1. Recently, Singh and Sareen also bioinformatically identified the 
flv cluster via the sequence similarity of FlvT to HalT (75), but this previous study did not 
characterize the enzymes or the products of the cluster nor discussed its unusual characteristics. 
Some features of the flv cluster are reminiscent of two-component lantibiotics but the high 
number of substrate genes with diverse sequences is not consistent with a typical two-component 
system. Previous reports on antimicrobial peptides produced by species from the Ruminococcus 
genus (13, 17, 76) suggested that the mature FlvA peptides could represent antimicrobial 
defenses of R. flavefaciens FD-1. In addition, previous studies of the lantibiotics ruminococcin A 
and butyrivibriocin OR79A (12, 14, 77) suggested that anaerobic bacteria associated with the 
digestive system are a source of bioactive lanthipeptides. Thus, characterization of the flv gene 
cluster and the resulting modified FlvA peptides was undertaken.  
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Unlike most previously characterized lanthipeptides, Flv peptide production from the 
native organism was not detected in appreciable amounts. This observation could be attributed to 
a lack of flv gene cluster expression under the laboratory culture conditions. Some evidence for 
this hypothesis is presented in the case of the lantibiotic ruminococcin A for which transcription 
of the biosynthetic genes in the native organism Ruminococcus gnavus E1 is dependent upon 
growth phase and the presence of trypsin (78). The variety of genetic contexts and regulatory 
elements associated with lanthipeptide biosynthetic gene clusters, discussed in Chapter 1, entails 
optimization of culture conditions or genetic tools for each native organism in order to access the 
products of the cluster. In order to circumvent the lack of observed production of the Flv 
peptides from R. flavefaciens FD-1, the established heterologous host E. coli was used for Flv 
peptide production. 
The structure of Flvα.a suggested by sequence homology and tandem MS data is 
consistent with those of other α-peptides of two-component systems. Although a general lack of 
fragmentation from the middle of the peptide to the C-terminus makes definitive assignment of 
the ring structure in this region difficult (Figure 2.7I), the ring pattern is very likely the same as 
those in Halα, Ltnα, and Licα (Figure 2.1C) (35, 42, 79). The most N-terminal Cys residue does 
not appear to be cyclized since fragmentation is observed on either side of the residue, and IAA 
assays showed the presence of two free Cys (Figure 2.7I and 2.9C). The possibility that these 
two Cys might be engaged in a disulfide bond was not supported by attempts to oxidatively 
cyclize them. 
Based on the results obtained from tandem MS and GC/MS, the modified FlvA2 peptides 
can be divided into two groups (Figure 2.12). The first group features an N-terminal ring, and the 
second category does not have the residues required to form this N-terminal ring. The 
assignment of Flvβ-peptides into the former group was based on the lack of fragmentation at the 
N-terminal extremity of these peptides as well as the LL stereochemistry of the Lan rings 
observed by GC/MS. Such a ring is also present in the β-peptides of haloduracin and 
lichenicidin, although the stereochemistry of the latter has not been reported (35, 42, 79). The 
central portion of all Flvβ-peptides contains a ring consisting of seven residues. The assignment 
of this ring is based on the tandem MS data that show a clear lack of fragmentation for all Flvβ-
peptides in this region (Figure 2.7). This ring also nearly aligns to the B ring of other two-
component peptides, but the latter feature a smaller five-amino-acid ring in this region (Figure 
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2.1D). The size of this central ring is not entirely clear for Flvβ.b, β.c, β.e, and β.g since a six-
amino-acid ring is also possible. However, formation of a seven-amino-acid ring is more likely 
based on Flvβ.a, β.d, β.f and β.h, which unambiguously contain such a ring. Also, comparison of 
the fragmentation patterns of Flvβ.b, β.c, β.e and β.g imply that one Ser/Thr within this region 
consistently escapes modification (Figure 2.12), suggesting the Ser/Thr that could result in a six-
amino-acid ring (underlined in Figure 2.12) is actually not dehydrated. 
 
 
Figure 2.12. Tandem MS fragmentation patterns and proposed structures of the modified FlvA core peptides. The 
FlvA peptides are divided into the categories that are discussed in the text, and the alignments highlight the similar 
ring topology of the peptides in each category. X = Dha or Ala, when engaged in a Lan, and Z = Dhb or Abu, when 
engaged in a MeLan. 
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Despite the different ring topologies observed in the FlvA2.x peptides, the heterologously 
expressed FlvT protein was able to proteolytically remove the leader peptide and export most of 
the FlvA2.x peptides. Furthermore, varying amounts of dehydration of each FlvA2.x peptide 
were observed in the supernatant of the FlvT, FlvM2, and FlvA2.x co-expressions (Figure 2.10), 
suggesting appreciable tolerance by FlvT for secondary structural variations in the core peptide. 
The sequence tolerance exhibited by FlvT was further illustrated by its ability to export the 
dehydrated core peptide of the related lantibiotic lichenicidin β (Figure 2.10). Lastly, the lack of 
observed in vitro activity for the Cys protease domain of FlvT could possibly be remediated by 
optimizing the site of truncation. In vitro reconstitution of FlvT activity could present a broad 
substrate protease capable of processing two-component β peptide-like sequences. The in vitro 
reconstitution and subsequent investigations of LanT enzymes may present an enabling 
alternative to the current array of leader peptide removal strategies. 
Two combinations of peptides resulted in synergistic bioactivity. Adding 2-Flvα.a to 
either Flvβ.b or -Flvβ.g resulted in clearly enhanced zones of growth inhibition. A comparison 
of the structures determined for Flvβ.b and -Flvβ.g indicates that the similarities are all in the 
C-terminal region, suggesting that this segment of the peptide is responsible for the interactions 
of the Flv peptides with the Flv peptide. This observation is in agreement with the extensive 
mutagenesis data on the -peptide of lacticin 3147 (80). Two possibilities were considered for 
the relatively low observed antibacterial activity. Perhaps the small deviations between the 
predicted leader peptide removal sites and the products obtained after in vitro leader peptide 
removal resulted in imperfect interactions of the peptides. We did not find this explanation very 
likely since the N-termini of the eight Flv-peptides (and other two-component lanthipeptides) 
are already highly heterogeneous by sequence (Figure 2.1D), and more importantly, the 
antimicrobial activity observed for the predicted Flvα.a and β.b core peptides was comparable to 
the combination of Flvα.a and β.b (Figure 2.9F). Alternatively, perhaps the flv cluster is a 
pseudo cluster. We find this possibility also highly unlikely. It seems no coincidence that the 
four copies of the -peptide are highly conserved, consistent with the general model of two-
component lantibiotics in which this peptide recognizes a structurally conserved target (lipid II, 
see Chapter 1). The observation that the cluster encodes four such copies and eight copies of the 
-peptides in light of a 1:2:2 stoichiometry observed for lipid II:Hal:Hal (32) also seems non-
coincidental, but attempts to obtain increased activity by various combinations of peptides have 
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thus far not been successful. The lack of robust antimicrobial activity seems especially puzzling 
given the presence of hallmark lipid II binding features in the Flvα.a peptide introduced in 
Chapter 1. However, since the activity of the two-component lantibiotics is dependent on the 
interaction of two separate polypeptides, the effects of differences in the primary structure of the 
Flvβ.x peptides, as compared to the β peptides of characterized two-component lantibiotics 
(Figure 2.1D), on antimicrobial activity are unclear. 
The weak observed activity may instead reflect our inability to identify the physiological 
target organism(s). Ruminal two-component lantibiotics may be much more fine-tuned for 
specific target organisms than observed in other environments. It has been reported that bacterial 
diversity in vertebrate-associated communities is quite different from that in soil or aquatic 
environments, with 16S rRNA gene-based trees indicating extensive diversity at the species level 
rather than at higher levels as observed in the latter environments (81-84). Perhaps such an 
environment has promoted the thus-far unique example of a multi-component lantibiotic system 
with eight diverse -peptides. The corollary of this hypothesis is that it may be very difficult to 
identify the specific physiological target organism of these peptides, especially if the flavecins 
exhibit the narrow target specificity that is not unusual for RiPPs (85, 86). In turn, this may 
explain the rather weak activity observed against the organisms tested thus far. At present, still 
very few lanthipeptide gene clusters are known from ruminant environments (87) and we have 
not observed any other two-component systems in the available genomes. As discussed below, 
this may be the result of the still limited available genome sequence information, and as more 
genomes are sequenced, additional such examples may be uncovered.  
The current work on the genetic capacity of R. flavefaciens FD-1 to produce a diverse set 
of eight different -peptides has similarities but also important differences compared to previous 
examples of combinatorial biosynthesis of lanthipeptides. In 2010, the first example was reported 
of a single enzyme making 30 different lanthipeptides in the cyanobacterium Prochloroccocus 
MIT 9313 (88). At the time this was a curious finding isolated to one genome, but in the 
intervening time as more genomes have been sequenced, this combinatorial biosynthesis has 
been found in many different cyanobacteria genera (25). To date, none of the products has shown 
any antimicrobial activities and the products have all had very different structures. In contrast, 
the example described here is clearly different. Firstly, the four copies of the -peptide are 
essentially identical and all contain the highly conserved lipid II binding motif (Figure 2.1C), 
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strongly suggesting that the products are antimicrobial peptides. Secondly, the system contains 
two enzymes that have clearly defined roles, unlike the one enzyme in the cyanobacterial 
systems that has evolved for promiscuity. Thirdly, unlike the one cyanobacterial enzyme, which 
in order to be able to accommodate a highly diverse set of substrates is a very slow enzyme (89), 
the FlvM2 enzyme is very efficient in processing the eight FlvA2.x substrates that are diverse in 
sequence, but that have maintained a certain core set of rings at the C-terminus. All of these 
observations point at a two-component lantibiotic system where the diversification of the -
peptides has been beneficial in the specific growth environment of the producer organism. 
In conclusion, this chapter presents the characterization of the ring topology and 
stereochemistry of nine different lanthipeptides encoded in the genome of R. flavefaciens FD-1. 
A subset of the modified Flvβ core peptides (Flvβ.b and -Flvβ.g) exhibited enhanced 
antibacterial activity when used in combination with Flvα.a, demonstrating that at least a subset 
of these peptides constitute two-component lantibiotic systems. Although the FlvA2 peptides 
display appreciable variation in their amino acid sequence, their post-translational modification 
is orchestrated by only one FlvM2 enzyme that is responsible for the modification of eight FlvA2 
peptides with quite diverse sequences and final ring topologies. Elucidation of the features of the 
Flv system sets the stage for more in depth investigation of the biological roles of this curious set 
of lanthipeptides. 
 
2.4 Materials and methods 
2.4.1 General materials and methods 
Molecular cloning reaction components were purchased from New England BioLabs 
(NEB) and included Phusion High-Fidelity DNA Polymerase, deoxynucleotide triphosphate 
mixture (dNTP) containing 10 mM of each deoxynucleotide, T4 DNA ligase. PCR and 
sequencing primers were ordered as custom oligonucleotide sequences from Integrated DNA 
Technologies. QIAquick PCR Purification Kit, QIAquick Gel Extraction Kit, and QIAprep Spin 
Miniprep Kit were purchased from Qiagen. For sequencing, the single pass primer extension 
sequencing service from ACGT, Inc. was used. Optima and LCMS grade acetonitrile (MeCN) 
was purchased from Fisher Scientific. 
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2.4.2 Cloning of flv genes 
Chemically competent DH5α E. coli cells were used to maintain plasmids while BL21 
(DE3) E. coli cells were used for the expression of constructs, which were assembled using a 
plasmid RSFDuet-1 backbone, except in the case of flvT. The flvT gene was incorporated into 
mcs1 of a plasmid ACYCDuet-1 backbone. Kanamycin was used at a final concentration of 50 
µg/mL in both solid and liquid media. All liquid cultures were incubated at 37 °C with agitation 
at 200-220 revolutions per minute (rpm). 
Polymerase chain reactions (PCRs) were run on a 20 µL scale and contained final 
concentrations of 1x Phusion HF Buffer (supplied with Phusion HF Polymerase), 3% v/v 
dimethylsulfoxide, 0.2 mM dNTPs, 0.5 µM of the forward and reverse primer, 56 ng of template 
DNA, and 10 U/mL of Phusion HF Polymerase. The PCRs were subjected to the following 
temperature (temp.) cycles: 30 s at 98 °C, 10 s at 98 °C, 30 s at the desired annealing temp., 30 
s/kb at 72 °C, 5 min at 72 °C, and 4 °C for storage. 
 
Table 2.2. Primers for cloning flv genes. 
Primer name Primer sequence 5′ to 3′ Annealing 
temp., °C 
FlvAII.1_F  
Rum68_f (bamHI) attactggatccgATGTCAGAGAAGAATATGGAAAAAG 51 
FlvAII.1_R  
Rum68_b (hindIII) attactaagcttTTACTTTCTTGGTAAAATCGG 48 
FlvAII.2_F  
Rum69_f (bamHI) attactggatccgATGGATAACAATACAAAATTACAGAAATTATAC 52 
FlvAII.2_R 
Rum69_b (hindIII) aatcctaagcttTCAAACTCTGCAAGAGTATGTGC 55 
FlvAII.3_F 
70_bam attactggatccgATGGAAAATAAATTCGATATGGAAAAATTC 52 
FlvAII.3_R 
70_afl attactcttaagTCAGAAACGGCAGGATGTTGTG 58 
FlvAII.4_F 
Rum71_f (bamHI) attactggatccgATGGATAACAATACTGAAAAATTCAACGAACTGGCAGC 58 
FlvAII.4_R 
Rum71_b (hindIII) attactcttaagTCAGAAACGGCAGGGCGGTG 58 
FlvAII.5_F 
Rum72_f (bamHI) attactggatccgATGAACAACAAGGAATTCAACATGGAACAG 58 
FlvAII.5_R 
Rum72_b (hindIII) attactaagcttTCAGAAACGGCAGGATGTTGTGCAAG 62 
FlvAII.6_F 
Rum73_f (bamHI) attactggatccgATGGAAAAGATGAACAATATAGCAGG 54 
FlvAII.6_F 
Rum73_b (hindIII) attactaagcttTCATAAAAGACGGCACTTCACTG 55 
FlvAII.7_F 
Rum74_f (bamHI) 
attactggatccgATGAACAACAATAACTTTGATATGGAAAAATTCAAGAA
G 57 
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Table 2.2. (cont.) 
FlvAII.7_R 
Rum74_b (hindIII) attactaagcttTCAGAAGCGGCAGGAGTGTGTGCAAG 65 
FlvAI.1_F 
Rum75/8_f 
(bamHI) attactggatccgATGAACAAGAACCCAATCTACAG 53 
FlvAI.1_R 
Rum75/8_b 
(hindIII) attactaagcttTTACTTGTTGCAGGTCTTTGAG 53 
FlvAII.8_F  
Rum79_f (bamHI) attactggatccgATGGAAAGATACGGACATTTAGCAGG 57 
FlvAII.8_R 
Rum79_b (hindIII) attactaagcttTTATAATCGGCATGAATACGTGCAAG 56 
FlvM1_F  
Rum81_f (asisI) attactgcgatcgcGTGGATCAGCAGAACACACAGATAG 57 
FlvM1_R 
Rum81_b (xho) attactctcgagTCACGTCAACCAAAGATGATC 53 
hisFlvM1_F(bamH
I) attactggatccgGTGGATCAGCAGAACACACAG 56 
hisFlvM1_R 
(aflII) attactcttaagTCACGTCAACCAAAGATGATCC 55 
FlvM2_F 
Rum82_f (ndeI) attactcatatgcaATGAAGCTGAATGAGATACATGATATCATAGACAACG 59 
FlvM2_R 
Rum82_b (xho) attactctcgagTCAGGATACAGCGAAAGCATATATC 54 
hisFlvM2_F 
(bamHI) attactggatccgATGAAGCTGAATGAGATACATGATATCATAGACAACG 59 
hisFlvM2_R(aflII) attactcttaagTCAGGATACAGCGAAAGCATATATCTCGCTATC 60 
FlvT_F (ecoRI) 
caccacagccaggatccgaattcaATGAATAGAAAATTAAGCGTACCAATGATAA
AAC 67 
FlvT_R (notI) ctgttcgacttaagcattatgcggccgcTTAAGCAGACCTCAGTCTGTTGTAAAGTG 67 
hisFlvT151_F 
(ndeI) 
cctggtgccgcgcggcagccatattATGAATAGAAAATTAAGCGTACCAATGATAA
AAC 67 
hisFlvT151_R 
(bamHI) ggccgcaagcttgtcgacggagctcgaattcggatccTTACACCCATATATTGGGGCCG 68 
 
Aliquots of 5 µL of all PCRs were visualized using a 1% agarose gel and a Bio-Rad 
Molecular Imager XR+ Gel Doc Imaging System using the accompanying Quantity One 4.6.9 
program. The remaining 15 µL of PCR sample was purified using a QIAquick PCR Purification 
Kit according to the manufacturer’s protocol. Plasmids were digested using restriction 
endonucleases purchased from NEB according to the manufacturer’s protocol and purified using 
a QIAquick Gel Extraction Kit also according to the manufacturer’s protocol. Ligation reactions 
were run on a 5 µL scale using a 1:10 ratio of plasmid to insert using the manufacturer 
conditions described for T4 DNA ligase reactions. Following a 1:8 dilution, 10 µL of the ligation 
reaction was transformed into chemically competent E. coli DH5α cells. Transformants were 
screened for the desired construct by culturing in liquid media, isolating the DNA with a 
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QIAprep Spin Miniprep Kit and sequencing. For Quickchange mutagenesis, the PCR sample was 
subjected to DpnI digestion before PCR Purification. The resulting DNA was transformed into E. 
coli DH5α cells, and cells containing mutated plasmid were screened as described above. 
 
2.4.3 Expression, IMAC, ZipTip, and MALDI-TOF-MS of Flv peptides 
Electrocompetent E. coli BL21 (DE3) cells were transformed with the construct(s) to be 
expressed and plated on antibiotic containing media. Single colony transformants were then 
inoculated into starter liquid LB cultures containing 50 µg/mL of kanamycin. The starter culture 
was incubated overnight and expression cultures were then inoculated with the starter culture. 
The expression cultures were incubated until an optical density as monitored at 600 nm (OD600) 
of 0.6-0.8 was achieved. A solution of isopropyl-β-D-galactopyranoside (1 M) was then added to 
the culture to achieve a final concentration of 1-0.5 mM. The expression culture was allowed to 
incubate for an additional 3-4 h. Cells from the expression culture were harvested by 
centrifugation at 5,000×g, 4 °C, for 15 min. The resulting pellet was stored at −80 °C until 
peptide purification was carried out. 
Purification of the FlvA peptides was carried out as previously described with the 
following modifications to the protocol (90). Briefly, the cell pellets were re-solubilized in 
denaturing LanA Buffer 1 (6 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 500 
mM sodium chloride, 0.5 mM imidazole) and lysed via sonication. After centrifugation of the 
lysate, the supernatant was clarified by filtration through a 0.45 µm membrane and subjected to 
IMAC. Desalting of the peptides in the eluent from IMAC was achieved through the use of 
Vydac BioSelect Solid Phase Extraction (SPE) Columns purchased from Grace (cat. no. 
214SPE3000). The columns were first wetted with 2 column volumes (CV) of 100% acetonitrile 
(ACN) then equilibrated with 2 CV of 99.9% water, 0.1% trifluoroacetic acid (TFA). The eluent 
from IMAC was passed through an SPE column and the column bed was washed with 4 CV of 
the equilibration solution. Desalted peptide was eluted from the column using 80% ACN, 19.9% 
water, 0.1% TFA. This solution was flash frozen and dried in vacuo to obtain a fluffy white 
solid. 
MALDI-TOF-MS analysis of desalted samples was completed using a Bruker 
UltrafleXtreme MALDI-TOFTOF-MS maintained in the UIUC School of Chemical Sciences 
Mass Spectrometry Laboratory. The Bruker flexControl and flexAnalysis programs were used 
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for data acquisition and analysis, respectively. The matrix suppression mode was set to 
deflection and the data was not subjected to processing. The instrument was calibrated before 
each use with Bruker Peptide Calibration Standard II or Protein Calibration Standard (Bruker 
Daltonics, Billerica, MA) prepared in the same way as the sample. For sample preparation, 0.5 
µL of desalted sample was spotted on a Bruker MTP 384 polished steel target plate with an equal 
volume of sinapic acid matrix (80% ACN, 19.9% water, 0.1% TFA, sinapic acid added until 
saturation). 
 Proteolysis reactions ranged in volume from 20 µL to 20 mL and contained final 
concentrations of 250 mM Tris-HCl, pH 7.5, 2 mg/mL of peptide, and 0.2-1 µg/mL of protease. 
After approximately 1 h incubation at room temp., the reactions were desalted by ZipTip, as per 
the manufacturer’s instruction (EMD Millipore). The content of the ZipTip was directly eluted 
onto a Bruker MTP 384 polished steel target plate with 1 µL of sinapic acid matrix. The sample 
was analyzed by MALDI-TOF-MS for the complete consumption of full length substrate 
peptide. The remainder of the peptide in the proteolysis reaction was desalted by SPE. 
 
2.4.4 Expression and IMAC of FlvM and FlvT proteins 
Expression of the FlvM and T proteins were carried out as described for the FlvA 
peptides, but instead of incubating at 37 °C after induction, the cells were incubated at 18 °C for 
18-22 h. After incubation, the cells were harvested in the same manner as described for peptide 
expressing cultures. Purification of the FlvM and T proteins was carried out as previously 
described with the following modifications to the protocols (90, 91). The sample was maintained 
either on ice or at 4 °C for the duration of the protocol. Briefly, the cell pellets were re-
solubilized in protein Start Buffer (LanM Start Buffer: 20 mM Tris, pH 7.6, 500 mM NaCl, 10% 
glycerol; LanT Start Buffer: 50 mM Na2HPO4, pH 7.5, 500 mM NaCl) and lysed using an 
Avestin EmulsiFlex-C3. After centrifugation of the lysate, the supernatant was clarified by 
filtration through a 0.45 µm membrane and subjected to IMAC using fast performance liquid 
chromatography (FPLC, Amersham Biosciences/GE Healthcare ÄKTA system) to provide a 
continuously increasing concentration of imidazole. Buffer exchange of the protein-containing 
eluent fractions from IMAC was achieved through the use of PD‐10 size exclusion 
chromatography (GE Healthcare) and protein Final Buffer (LanM Final Buffer: 20 mM Tris, pH 
7.6, 500 mM KCl, 10% glycerol; LanT Final Buffer: 50 mM Na2HPO4, pH 7.5, 500 mM NaCl, 
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10% glycerol). The concentration of protein was determined by monitoring the absorbance at 
280 nM, and the protein solution was flash frozen and stored at −80 °C until in vitro assays were 
carried out. 
 
2.4.5 IAA assays of FlvA peptides 
 The LanM in vitro and IAA assay reaction conditions were adapted from previous 
reports. In vitro reactions were setup using final concentrations of 200 mM HEPES, pH 8, 10 
mM TCEP, 10 mM magnesium chloride, 5 mM adenosine triphosphate, 0.5-1 mg/mL of peptide, 
and 10-30 µg/mL of FlvM enzyme. Reactions ranged from 20 µL to 20 mL in volume. IAA 
assays were setup on a 20 µL volume using final concentrations of 250 mM HEPES, pH 9, 13 
mM TCEP, 0.25 mg/mL of peptide, and 25 mM IAA. Reactions were allowed to incubate at 
room temp. for 1 h. For both types of reactions, reaction progress was monitored by ZipTip and 
MALDI-TOF-MS analysis as described above. In the case of the LanM reactions, the reactions 
were allowed to incubate at room temp. for additional time until the starting material peptide was 
no longer observed by MALDI-TOF-MS. 
 
2.4.6 Preparation and MALDI-TOF-MS of FlvT co-expression samples 
 The pellet was removed from cultures obtained after the co-expression of FlvM2, A2.g 
and T by centrifugation at 11,900 ×g. The supernatant was then decanted and subjected to 
ZipTip and MALDI-TOF-MS analysis as stated above. 
 
2.4.7 HPLC of FlvA peptides 
Analytical scale RP-HPLC was completed using an Agilient 1260 Infinity equipped with 
a Phenomenex Luna column (10 µm, C18(2), 100 Å, 250×4.6 mm) and managed using Agilent 
Instrument 1 (Online) software. Semi-preparative scale RP-HPLC was performed using a 
Shimadzu Prominence equipped with a Phenomenex Luna column (10 µm, C18(2), 100 Å, 
250×10.0 mm), managed using the Shimadzu program LC Real Time Analysis. A solvent system 
of A: 99.9% water, 0.1% TFA, B: 80% MeCN, 19.9% water, and 0.1% TFA was used. The 
gradient consisted of 0-5 min 2% B, 5-50 min 0-100% B, 50-60 min 2-100% B, and 60-65 min 
100-2% B was used to purify the peptides. The core and GluC fragments of the FlvA peptides 
typically eluted between 30-40 min of the gradient. The resulting fractions of interest were 
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determined by MALDI-TOF-MS analysis, pooled, flash frozen and dried in vacuo, which 
yielded fluffy white solids. 
 
2.4.8 Proteolysis of FlvA peptides 
GluC was purchased from Roche Diagnostics (cat. no. 10791156001) and 
aminopeptidase was purchased from Sigma-Aldrich (cat. no. A8200-100UN). Both proteases 
were reconstituted using Milli-Q water to a final concentration of 10 mg/mL and 1 U/mL, 
respectively. Proteolysis reactions were carried out in 50-100 mM Tris-HCl, pH 8.0 with final 
concentrations of 1 mg/mL peptide and 0.04 mg/mL or 0.02 U/mL of protease. Reactions ranged 
in scale from 20 µL to 40 mL, and were incubated at room temp. for 12-18 h and analyzed by 
MALDI-TOF-MS. Proteolysis reactions were subjected to desalting and the peptide product was 
purified using RP-HPLC and dried as previously described. 
 
2.4.9 Hydrolysis, derivatization, and GC/MS analysis of FlvA peptides 
Peptide hydrolysis and amino acid derivatization was carried out as previously described 
(63). Briefly, the peptide was hydrolyzed in a sealed tube in 3 mL of 6 M HCl at 110 °C for 8-12 
h. The hydrolysate was dried in vacuo and combined with a mixture of acetyl chloride that had 
been added drop-wise to 1.5 mL of methanol (MeOH). This reaction was refluxed at 110 °C for 
45 min and then dried in vacuo. Then 3 mL of dichloromethane was added to the resulting 
residue, followed by the addition at 0 °C of 1 mL of pentafluoropropionic anhydride. The 
reaction was refluxed for 15 min at 110 °C, dried in vacuo, and stored at −80 °C until GC/MS 
analysis was performed. Prior to analysis, the sample was re-dissolved in 100 µL of MeOH. 
Particulates were removed by centrifugation at 23,700×g for 4 min, and the resulting supernatant 
was transferred into a glass insert and vial compatible with the instrument. 
GC/MS analysis was performed using an Agilent Hewlett Packard 5973 mass 
spectrometer equipped with a CP-Chirasil-L Val column (25 m, 0.25 mm, 0.12 µm, 7 inch cage; 
Agilent Technologies). The initial oven temp. was 160 °C for 5 min followed by a gradient over 
1 min to a final temp. of 180 °C, and then this temp. was maintained for 10 min. Sample was 
introduced into the instrument via a split (1:5) 2-5 µL injection with a flow rate of 2.0 mL/min 
helium gas. The initial inlet temp. was 190 °C, the MSD transfer line heater temp. was 185 °C, 
the MS Quad analyzer temp. was 150 °C, and the ion source temp was 230 °C. Scan and selected 
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ion monitoring at 365 Da and 379 Da data was acquired. To further confirm the identity of the 
species observed, authentic (Me)Lan standards of known stereochemistry were added to the 
samples and the resulting mixture was analyzed. Care was taken to dilute the samples or 
standards such that signal arising from (Me)Lan standard was comparable in intensity to that 
arising from the sample. 
 
2.4.10 Tandem MS analysis of FlvA peptides 
A Waters Synapt ESI-QTOF coupled to an Acquity ultra high performance liquid 
chromatography (UPLC) system was used for tandem mass spectrometry analysis. The UPLC 
was equipped with an Acquity UPLC BEH column (C8 1.7 µm 1.0×100 mm). The UPLC 
solvents used were A: 99.9% water, 0.1% formic acid (FA) and B: 99.9% MeCN, 0.1% FA. A 
gradient of 0-2 min 2% B, 2-12 min 2-98% B, 12-15 min 98% B, was employed. Tuning, 
calibration, and data acquisition was accomplished using the Waters MassLynx V4.1 program. 
Prior to sample analysis, the instrument was tuned and calibrated using a 0.1% phosphoric acid 
solution. All samples were run using [Glu1]-Fibrinopeptide B human (Sigma-Aldrich) as an 
external calibrant. Dried samples obtained after RP-HPLC were prepared for analysis by re-
dissolving in Milli-Q water and transferring to a glass vial compatible with the UPLC system. 
Prior to tandem mass spectrometry, parent masses were verified by ms1 to be within 5 ppm of 
the calculated mass. Collision induced dissociation was used with a collision energy ramp 
ranging from 15-55 eV. Data analysis was completed using MassLynx V4.1 and the BioLynx 
Protein/Peptide editor. 
 
2.4.11 Culturing the anaerobic bacterium R. flavefaciens FD-1 
Liquid media was used to culture R. flavefaciens FD-1 (4.0 g of cellobiose, 2.0 g Bacto-
tryptone, 50 mL mineral solution 1, 50 mL mineral solution 2, 10 mL volatile fatty acid solution 
in 820 mL of distilled water. After autoclaving but prior to inoculation 50 mL of an 8% sodium 
carbonate solution and 20 mL of a 1.25% cysteine-sulfide solution was added.  
Mineral solution 1 consisted of 3.0 g potassium phosphate monobasic in 500 mL of 
distilled water; mineral solution 2 consisted of 3.0 g potassium phosphate monobasic, 6.0 g of 
sodium chloride, 0.6 g of magnesium sulfate, 0.6 g of calcium chloride dihyrdate, 6.0 g of 
ammonium sulfate in 500 mL of distilled water. The volatile fatty acid solution consisted of 6.85 
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mL of acetic acid, 3.0 mL of propionic acid, 1.84 mL of butyric acid, 0.55 mL of 2-
methylbutyric acid, 0.47 mL of isobutyric acid, 0.55 mL of valeric acid, 0.55 mL of isovaleric 
acid, adjusted to pH 7.5 using sodium hydroxide and a final volume of 500 mL with distilled 
water. 
Culturing procedures were performed using anaerobic technique and as previously 
described (19). R. flavefaciens FD-1 was inoculated directly into liquid media from revived 
glycerol stocks. Inoculated liquid cultures were incubated at 37 °C for 36-48 h. Subsequent steps 
were performed under aerobic conditions. The cells were pelleted by centrifugation at 11,900 ×g, 
4 °C, for 10 min, and the resulting supernatant was subjected to ZipTip and MALDI-TOF-MS 
analysis for the presence of peptides. For solid medium co-culturing studies, 2 µL of each of the 
R. flavefaciens FD-1 and R. albus 7 liquid cultures was inoculated in close proximity on solid 
media. The plate was incubated for 24 h before colony MALDI-TOF-MS analysis. The samples 
were prepared by analyzing a small quantity of the proximal and distal (to the R. albus 7 colony) 
portion of the R. flavefaciens FD-1 colony and placing it on a Bruker MTP 384 polished steel 
target plate. One microliter of sinapic acid matrix was dispensed irectly on top of the sample and 
the sample was allowed to dry. 
Aerobic agar diffusion assay media components were purchased from Becton, Dickinson 
and Company. Solid media was prepared with a 1.5% w/v final concentration of agar purchased 
from Fisher Scientific (cat. no. BP1423-500). All procedures were performed aseptically. 
Organisms were maintained as 40% glycerol stocks at −80 °C. The glycerol stocks were revived 
by first streaking onto solid media and incubating at 37 °C for 16-20 h. A single colony of the 
organism was transferred into 5 mL of liquid media and incubated at 37 °C, 200-220 rpm for 12-
16 h. Agar diffusion assay plates were prepared by seeding 20 mL of molten solid media (~42 
°C) with 50 µL of the overnight liquid culture.  Following thorough mixing, the seeded solution 
was poured into a petri dish and allowed to solidify at room temp. Samples to be assayed were 
dissolved in DMSO and 1 µL aliquots were spotted directly onto the solidified media. When two 
peptide solutions were combined, only 0.5 µL aliquots of each solution were spotted in a single 
area. The ∆2-FlvA1.a peptide was assayed at a concentration of 1 mM while the FlvA2.x 
peptides were assayed at a concentration of 0.5 mM. Nisin was assayed at a concentration of 100 
µM and 0.2 µL of the solution was spotted on the plate. Once all spots were dry, the petri dish 
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was incubated at 37 °C for 16-20 h prior to visualization using a Bio-Rad Molecular Imager XR+ 
Gel Doc Imaging System and the accompanying Quantity One 4.6.9 program. 
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Chapter 3.  Identification of venezuelin-like peptides from Actinobacteria
*
 
 
3.1 Introduction 
As discussed in Chapter 1, lanthipeptides are widely distributed in taxonomically distant 
species and display very diverse biological activities, ranging from antimicrobial to antiallodynic 
(1-3). Four classes of biosynthetic enzymes are known to catalyze lanthionine formation (4, 5). 
The four distinct classes of biosynthetic machinery reflect the functional importance of 
lanthionine scaffolds and a convergent evolution process to produce them. Notably, products 
generated by these four classes of lanthionine synthetases are not limited to lanthipeptides. For 
example, many lanthipeptide-like biosynthetic gene clusters encode precursor peptides that have 
no Cys residues, and their products are therefore not lanthipeptides (6). 
Over the past 5 years, several studies have reported bioinformatics genome mining efforts 
based on the then-available genomes. These studies have typically focused on an enzyme-
specific query, such as class I LanB and LanC enzymes (7), class II LanM proteins (8), or the 
bifunctional LanT proteins, which transport lanthipeptides and remove their leader sequences 
(9). Building on the recent natural product gene cluster family (GCF) project (10), this chapter 
presents a large-scale analysis of lanthipeptide-like biosynthetic gene clusters that is driven by 
similarities in entire clusters rather than specific enzymes. We focused the analysis on 
lanthipeptides from Actinobacteria, which are relatively understudied compared to family 
members from Firmicutes. Actinobacteria carry a wealth of natural product biosynthetic gene 
clusters whose products encompass highly diverse chemical structures. 
This phylum has been the source and/or inspiration for the majority of pharmaceutically 
useful natural products (11). Although Actinobacteria constitute only a small proportion of 
known lanthipeptide producers, they encode a diverse set of post-translational modifications that 
have not been observed for lanthipeptides from other phyla (4) (e.g., lysinoalanine formation in 
cinnamycin (12), tryptophan chlorination and proline dihydroxylation in microbisporicin (13, 14) 
also called NAI-107 (15)), and glycosylation in NAI-112 (16). The unique modifications in 
                                                 
*
 Portions are reproduced with permission from 181. Zhang, Q., Doroghazi, J.R., Zhao, X., Walker, M.C., and van 
der Donk, W.A. (2015). Expanded natural product diversity revealed by analysis of lanthipeptide-like gene clusters 
in Actinobacteria. Appl. Environ. Microbiol. 81, 4339-4350. Studies were performed in collaboration with Dr. J. 
Doroghazi, Dr. Q. Zhang, and Dr. M. Walker. Dr. Doroghazi conceived of and constructed the GCF networks. Dr. 
Q. Zhang, and Dr. M. Walker analyzed all members of the GCFs. X. Zhao identified, isolated, and characterized the 
SapB and venezuelin peptides. 
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actinobacterial lanthipeptide biosynthesis suggest great potential for exploring unknown 
lanthipeptide chemical space in this phylum. 
 
3.2 Results 
3.2.1 SapB identification from Actinobacteria 
 Of the Actinobacteria screened, several strains yielded ions with masses that 
corresponded to putative core peptides from GCF31 (Figure 3.1), and this GCF corresponds to 
that of the morphogenic peptide SapB. Since the fragmentation pattern of the 2027 m/z ion from 
a member of GCF31, Streptomyces species S-1833, was nearly identical to that reported by 
Kodani and co-workers for SapB (Figure 3.2) (17), further characterization of the compound was 
not pursued. The ubiquity of SapB-like compounds is also evidenced in the observations of 
Dorrestein and co-workers (18). 
 
Figure 3.1. Lanthipeptide gene cluster family similarity network for Actinobacteria. Lanthipeptide gene cluster 
families discussed in (19) are shown in blue, and gene cluster families with previously characterized members or 
close analogs are shown in red. GCFs are labeled with their respective numbers whereas gene clusters not belonging 
to families (i.e. singletons) are labeled with their cluster identifier. GCFs in grey are not discussed in this chapter nor 
(19), but can be found on the website http://www.igb.illinois.edu/labs/metcalf/gcf/lant.html., together with their 
GCF numbers. To access the genes in the singleton clusters on the website, mouse over the singleton to show the 
GCF number. For instance, the very first singleton is Saci8_3. Then click Search at the top, and enter Saci8_3 in the  
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Figure 3.1. (cont.) 
search field for Gene Cluster Search. Then submit and click on the Saci8_3 link that appears. Previously 
characterized lanthipeptides or their analogs that are found in GCF31: SapB and various peptins (class III 
lanthipeptides); GCF22: actagardine (class II); GCF45: microbisporicin (class I); B24243_34 from Streptomyces 
africanus B‐24243 is similar to cinnamycin (72% identical LanAs, class II); SACE_22: erythreapeptin from 
Saccharopolyspora erythraea NRRL 2338 (class III); FrEUN1fDRAFT_20 from Frankia sp. EUN1f is similar to 
cinnamycin (54% identical LanAs; class II). Figure was made by Dr. J. Doroghazi. 
 
 
In our mass spectrometric screen of Actinobacteria, correlation of a predicted gene 
cluster and observed ion in the absence of fragmentation data was complicated by the inability to 
accurately calculate a putative mass, which was due to uncertainty regarding the length of the 
leader peptides. Cleavage sites and the potential for post-translational modifications that did not 
resemble characterized ones result in substantial shifts in calculated masses. Although more 
automated tandem MS data acquisition could overcome the necessity of accurate parent mass 
calculation, low production or silent gene clusters would remain problematic. 
 
Figure 3.2. Fragmentation pattern of SapB. Tandem MS spectrum of (A) previously reported SapB. Panel A 
reproduced with permission from (17), copywrite (2004) National Academy of Sciences, U.S.A. (B) Fragmentation 
of SapB isolated from S. species S-1833. 
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However, the GCF organization allowed for indirect correlation of masses with a gene cluster 
shared among several Actinobacteria. This approach is illustrated by the set of masses in the 
1700-2200 m/z range observed from a set of the Actinobacteria that share a class IV, venezuelin-
like gene cluster (Figure 3.3A, B, E). 
 
3.2.2 Identification and characterization of class IV lanthipeptides 
At the time of this study, venezuelin had been obtained only via in vitro modification of 
the precursor peptide VenA by VenL followed by proteolytic removal of the leader peptide (20). 
However, production of venezuelin was detected neither in the wild-type strain S. venezuelae nor 
after attempted expression of the gene cluster in S. lividans, raising the question whether 
venezuelin is a genuine natural lanthipeptide. In our current analysis, we noted that GCF147 (33 
members) (Figure 3.1) consists mostly of venezuelin-like gene clusters (Figure 3.3C), and the 
putative precursor peptide sequences are highly conserved (Figure 3.3D), suggesting the wide 
occurrence of venezuelin-like lanthipeptide gene clusters (although it was first discovered in S. 
venezuelae, here we collectively designate all these similar putative lanthipeptides venezuelins). 
The conserved genes in GCF147 include a lanA gene, a lanL gene, and two ABC transporter 
genes (Figure 3.3C), indicating that (Me)Lan formation is likely the only post-translational 
modification on LanA core peptides in this family. Three Streptomyces strains (S. katrae 
ISP5550, S. lavendulae subsp. lavendulae NRRL B-2508, and S. sp. strain NRRL B-2375) 
produced venezuelins in detectable amounts (Figure 3.3A, B, E). Venezuelins of different 
lengths were detected, similar to the observations with class III lanthipeptides (21-24). The 
variation in lengths of the observed venezuelins corresponded to the presence or absence of 
Phe28 and Ala29 (numbering based on VenA sequence) (Figure 3.3A, B, E), presumably arising 
from stepwise removal of (part of) the leader peptides. 
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Figure 3.3. MALDI-TOF MS detection of venezuelins in Actinobacteria. Spectra from colony MS of (A) S. species 
B‐2375, (B) S. lavendulae subspecies lavendulae B‐2508, and (C) representative gene clusters of GCF147. (D) A 
logo depicting the GCF147 precursor peptide sequences. (E) MALDI-TOF MS analysis of venezuelin produced by 
S. katrae ISP5550. (F) ESI-MS-MS analysis of venezuelin produced by S. katrae ISP5550. The lack of 
fragmentation is consistent with a globular, overlapping ring topology. 
 
 
2221.28 
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The venezuelin from S. katrae ISP5550, which contained Ala29 at its N-terminus, was 
further analyzed by electrospray ionization (ESI)-MS-MS analysis (Figure 3.3F). The lack of any 
fragmentation showed that the peptide likely consists of overlapping (Me)Lan rings, consistent 
with the previously proposed ring topology of venezuelins based on extensive mutagenesis 
studies (20). Additional verification that venezuelin from S. katrae ISP5550 is indeed a 
lanthipeptide was provided by hydrolysis of the peptide and derivatization of the constituent 
amino acids as methyl esters and pentafluoropropionamides (25, 26). Chiral GC-MS analysis of 
the derivatized amino acids revealed the presence of (Me)Lan, supporting the designation of 
venezuelin as a lanthipeptide (Figure 3.4). The (Me)Lan derivatives all had the DL configuration. 
 
 
Figure 3.4. Chiral GC-MS analysis of hydrolyzed and derivatized venezuelin residues, which revealed the presence 
of DL-Lan and DL-MeLan. Trace i, sample showing the presence of DL-lanthionine obtained from venezuelin; trace 
ii, sample spiked with DL-Lan standard; trace iii, sample showing the presence of DL-MeLan obtained from 
venezuelin; trace iv, sample spiked with DL-MeLan standard. 
 
 
Our analysis validates that venezuelins are genuine natural products, and based on the 
frequency of their biosynthetic genes (Figure 3.1), they may be produced by many 
Actinobacteria. This observation also further supports the previous suggestion that identification 
of the products of silent clusters may be accomplished by screening several strains that contain 
the GCF (10).  
 
3.3 Discussion 
 Lanthipeptides are an intriguing class of natural products not only because of their 
potential medicinal values but also because of their wide occurrence and suitability for genome 
mining and heterologous expression studies. The identification of venezuelin from S. katrae 
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ISP5550, S. lavendulae subsp. lavendulae NRRL B-2508, and S. sp. strain NRRL B-2375 was 
greatly facilitated by the GCFs. Also, the organization allowed for intuitive appreciation of the 
biosynthetic diversity, an aspect of bioinformatics discussed in Chapter 1. The study presented 
herein highlights how bioinformatic organization of genome information complements and 
accelerates discovery efforts. 
The low frequency of masses corresponding to putative products can be attributed to the 
recalcitrant or silent nature of biosynthetic gene clusters, which was observed in the original 
report of venezuelin (20). Most of the class III lanthipeptides reported thus far from 
Actinobacteria have no or weak antimicrobial activities, and quite a few have anti-
allodynic/antinociceptive activity (16, 21) or morphogenetic activities (27). Since the 
venezuelins did not display antimicrobial activity in a previous study (20), class IV 
lanthipeptides may also have activities that would have eluded antimicrobial screens. Some 
evidence for this was presented upon isolation of larger quantities of another class IV 
lanthipeptide, streptocollin. Although this peptide did not exhibit antimicrobial, antiviral, or 
morphogenetic activity, it did inhibit protein tyrosine phosphatase 1B, which is involved in 
signaling pathways (28). 
 
3.4 Materials and methods 
3.4.1 Colony MS 
A small portion (approximately 1x1 mm) of colony was transferred onto a Bruker MTP 
384 polished steel target plate. On top of the colony, 2 µL of sinapic acid matrix was overlaid 
and allowed to air dry. Sinapic acid matrix was prepared by saturating an 80 acetonitrile 
(MeCN): 20 Milli-Q water solution with sinapic acid (Sigma-Aldrich). MALDI-TOF MS 
instrumentation, software, and calibration were the same as described in Chapter 2, Materials and 
methods section. 
 
3.4.2 Solid cultures of S. katrae ISP5550 
DMSO stocks of S. katrae ISP5550 were prepared by mixing 600 µL of a S. katrae 
ISP5550 liquid culture with an equal volume of sterilized 20% dimethyl sulfoxide (DMSO). The 
resulting solution was mixed, flash frozen, and stored at −80 °C. S. katrae ISP5550 was 
inoculated from DMSO stocks onto solid ATCC172 media (20 g soluble starch, 5 g yeast extract, 
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5 g N-Z amine type A, 1 g calcium carbonate, 15 g agar, 1 L of Milli-Q water, after autoclaving 
the media, sterilized glucose was added to a 1% final concentration) and incubated at 30 °C for 
4-5 days. The presence of venezuelins was detected using colony MALDI-TOF-MS as described 
in the preceding paragraph. 
 
3.4.3 Liquid cultures of S. katrae ISP5550 
Upon detection of venezuelins by colony MALDI-TOF-MS from solid cultures of S.  
katrae ISP5550, liquid cultures were analyzed for the production of venezuelins. A single colony 
was transferred into 50-100 mL of liquid ATCC172 media, prepared in the same way as the solid 
media with the omission of agar. The liquid culture was incubated with shaking at 30 °C for 12 
days. Supernatant from the liquid cultures was obtained by centrifuging at 4,650 ×g for 15 min. 
The hydrophobic components of the supernatant were desalted by ZipTip (EMD Millipore) 
according to the manufacturer’s instructions. The ZipTip contents were directly eluted onto a 
Bruker MTP 384 polished steel target plate on a spot containing 1 µL of sinapic acid matrix. 
Analysis by MALDI-TOF-MS was performed as described above.  
In preparation for ESI MS, peptide components of the supernatant were precipitated 
using ammonium sulfate. A 60% final concentration of ammonium sulfate was achieved with the 
addition of 30 g of ammonium sulfate to 50 mL of supernatant. The solution was allowed to 
incubate at room temperature for 30 min. The resulting precipitate was pelleted by centrifugation 
at 22,789 ×g for 10 min, and the supernatant was decanted. The pellet was re-dissolved in Milli-
Q water and subjected to ESI-MS analysis using an Acquity ultra performance liquid 
chromatography (UPLC) system coupled to a Waters Synapt ESI-QTOF. The UPLC was 
equipped with an Acquity UPLC BEH C8 1.7 µm 1.0×100 mm column. Sample was introduced 
into the column via an Acquity autoinjector and subjected to a gradient of 2% B from 0-2 min, 
2%-98% B from 2-12 min, and 98% B from 12-15 min (A was 0.1% formic acid in water and B 
was 0.1% formic acid in MeCN). The Waters MassLynx V4.1 program was used to tune, 
calibrate and acquire data. [Glu1]-Fibrinopeptide B human (Sigma-Aldrich) was used as an 
external calibrant and the mass of venezuelin was verified to be within 5 ppm of its calculated 
mass. Collision induced dissociation was achieved using a series of energy ramps ranging from 
30-60 eV. 
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3.4.4 Isolation of venezuelins 
S. katrae ISP5550 liquid culture supernatant was subjected to pressure-based sample 
concentration rather than ammonium sulfate precipitation. After centrifugation, 40 mL of culture 
supernatant was further clarified by filtration through a 0.22 µm nylon membrane and then 
loaded into an Amicon stirred cell equipped with a 1 kDa nominal molecular weight limit 
regenerated cellulose disc (EMD Millipore). The clarified supernatant was concentrated at room 
temperature from a volume of 40 to 2 mL over approximately 4 h. The concentrated supernatant 
was flash frozen and stored at −20 °C prior to fractionation by analytical reversed phase high 
performance liquid chromatography (HPLC) using an Agilent 1260 Infinity equipped with a 
Phenomenex Luna 10 µm, C18(2) 100 Å, 250×4.6 mm column. The instrument was managed 
using Agilent Instrument 1 (Online) software. The mobile phase consisted of A: 0.1% 
trifluoroacetic acid (TFA, Acros Organics) in water and B: 0.1% TFA in 80% MeCN, 20% water 
and a gradient of 2% B from 0-5 min, 2-100% B from 5-50 min and 100% B from 50-60 min. A 
0.5 µL aliquot of fractions eluting after 20 min was spotted with an equal volume of sinapic acid 
matrix and analyzed by MALDI-TOF-MS for the presence of venezuelin. Venezuelin-containing 
fractions (typically eluting at 35-38 min) were flash frozen and dried in vacuo. Three 1 mL 
injections of concentrated S. katrae ISP5550 supernatant yielded 100 µg of HPLC-purified, dry 
material. 
 
3.4.5 Detection of (Me)Lan in venezuelin 
HPLC-purified venezuelin was analyzed by GC/MS as previously described in Chapter 2. 
In brief, the sample was re-dissolved in 3 mL of 6 M HCl and heated at 110 °C for 10-12 h. The 
reaction was dried and mixed with a solution of acetyl chloride (Sigma-Aldrich) and methanol. 
Following reflux at 110 °C for 45 min, the reaction was dried and 3 mL of dichloromethane 
(Sigma-Aldrich) was added. After cooling the solution to 0 °C, 1 mL of pentafluoropropionic 
anhydride (Sigma-Aldrich) was added and the reaction was refluxed for 15 min at 110 °C. The 
reaction was dried and stored at −80 °C, and prior to GC/MS analysis the sample was re-
dissolved in 100 µL of methanol. Particulates were removed by centrifugation at 23,700 ×g for 4 
min. An Agilent Hewlett Packard 5973 mass spectrometer equipped with a CP-Chirasil-L Val, 
25 m, 0.25 mm, 0.12 µm, 7 inch cage (Agilent Technologies) was used to perform the GC/MS 
analysis. The sample was introduced to the instrument via a split (1:5) injection of 2-5 µL with a 
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2.0 mL/min helium gas flow rate. The initial inlet temperature was 190 °C and a gradient of 20 
°C/min from 160 °C for 5 min to 180 °C for 10 min was used. The following mass spectrometer 
settings were used: 185 °C for the MSD transfer line heater, 150 °C for the MS Quad analyzer, 
and 230 °C for the ion source. Data was acquired using scan and selected ion monitoring at 365 
and 379 Da. The identity of (Me)Lan residues was confirmed by adding authentic (Me)Lan 
standards to the sample and analyzing the resulting mixture by GC/MS. The mixtures of sample 
and standard were prepared such that there was an approximately equal contribution of signal 
arising from the sample and standard. 
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Chapter 4. Characterization of a hybrid RiPP gene cluster from Lachnospiraceae C6A11
*
 
 
4.1 Introduction 
Bioinformatic surveys have revealed that LanM as well as YcaO proteins are encoded in 
a variety of genomic contexts (1, 2). Both enzyme classes are associated with RiPP biosynthesis, 
with LanM proteins catalyzing Ser/Thr dehydration and in most cases cyclization reactions with 
Cys residues (3, 4). YcaO proteins, synonymous to D proteins (5, 6), are associated with the 
installation of oxazol(ine) and thiazol(ine) post-translational modifications in a variety of 
substrates including linear azol(in)e-containing peptides, cyanobactins, thiopeptides, and 
bottromycins (7). Among the characterized examples of LanM and YcaO enzymes and systems, 
there are no reported cases of systems in which LanM and YcaO proteins coordinate their 
activities. 
It was recently demonstrated that the coordination of oxazol(ine) and thiazol(ine) 
installing enzymes and lanthipeptide synthase proteins occurs during the biosynthesis of the 
thiopeptides (8). The representative Tbt system that generates the scaffold for thiomuracin 
consists of a set of proteins involved in dehydration (TbtB and C), two proteins involved in 
cyclodehydration (TbtF and G), one thiazoline dehydrogenase (TbtE), and a [4+2] cycloaddition 
enzyme (TbtD). TbtB and C bioinformatically correspond to the glutamylation and elimination 
domains of LanB proteins discussed in Chapter 1 and hence TbtB and C were designated as a 
split LanB. Through in vitro reconstitution, the order of post-translational modification was 
established as cyclodehydration of the substrate TbtA first by TbtF and G followed by 
dehydration by TbtB and C (8). In contrast to the dehydration reactions, cyclodehydration is a 
leader peptide dependent processes, while the former rely on a substrate conformation endowed 
by thiazole installation (9). Intriguingly, genome mining indicates the presence of LanM 
enzymes in clusters that also encode for YcaO-like proteins as shown in this chapter. Although it 
is tempting to project the findings from thiopeptide biosynthesis onto these systems, the 
fundamental variations between the two types of hybrid systems suggest possible differences in 
biosynthetic details. 
                                                 
*
 Studies were done in collaboration with Dr. Liujie Huo. Dr. Huo cloned the lahA genes and heterologously 
expressed them, purified the MBP-LahM1 fusion protein, and conducted the in vitro assays. X. Zhao cloned the 
genes for the LahM1, M2, and  D1 proteins; heterologously co-expressed these proteins with various LahA peptides 
and optimized the production of the LahM2 protein. 
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4.2 Results 
4.2.1 Bioinformatic identification and analysis of the Lah gene cluster 
The lah gene cluster encoded within the genome of Lachnospiraceae C6A11 presents an 
intriguing compilation of RiPP post-translational modification genes (Figure 4.1A). The cluster 
can be independently identified from the results of BLAST queries of BsjM and FlvM1 or M2.  
 
 
 
 
 
Although the pair of LanM proteins (annotated as LahM1 and M2) encoded within the lah gene 
cluster can be identified using BLAST, their domain architecture deviates from those of 
canonical LanM proteins (Figure 4.2). pFAM analysis of a prototypical LanM indicates the 
Figure 4.1. The lah gene cluster contains multiple enzymes and substrates. (A) lah gene cluster and (B) 
alignment of the LahA core peptides with Ser and Thr residues shown in red and Cys residues in blue. (C) LahA 
leader peptide alignment. 
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presence of an approximately 400 amino acid long N-terminal domain of unknown function 
(Duf4135) and an approximately 350 amino acid long LanC-like domain. These annotated 
domains roughly correspond to the dehydratase (i.e. kinase and lyase) and cyclase domains 
within the CylM crystal structure that was discussed in Chapter 1. pFAM analysis of both 
LahM1 and M2 reveals the presence of a dehydratase domain. However, the dehydratase domain 
is shorter (approximately 200 amino acids in length) and a second (approximately 100 amino 
acid) dehydratase domain appears to be located immediately after (Figure 4.2A). Alignment of 
each of the LahM and canonical (CylM and LctM) dehydratase domains indicates conservation 
primarily in the region that corresponds to the N-lobe of the CylM crystal structure (10). 
Furthermore, the cyclase domain of both enzymes is not annotated by pFAM, and alignment with 
previously characterized LanM proteins confirms the absence of the Zn-binding residues 
conserved in prototypical LanM proteins (11). Inspection of the dehydratase domain in the 
alignment indicates conservation of residues characterized to be involved in phosphate 
elimination for LahM1 but not LahM2 (Figure 4.2B) (10, 12). 
 
 
 
 
 
 
 
 
Figure 4.2. The LahM enzymes differ from canonical LanMs. (A) pFAM domain architecture of various LanM 
proteins compared to LahM1 and M2. (B) Alignment of canonical LanM enzymes (LctM and CylM), BsjM, and 
LahM1 and M2. Conserved residues that differ between the canonical enzymes and the others are shown in red 
for the dehydratase domain and green for the cyclization domain. Numbered residues correspond to the CylM 
sequence. 
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Additional enzymes encoded in the cluster include a flavin-dependent oxidoreductase 
(LahJB) and two YcaO proteins (Figure 4.1A). As mentioned in chapter 1, characterized LanJ 
orthologs are responsible for the reduction of dehydro amino acids to their corresponding D-
amino acid counterparts (4, 13). The YcaO proteins, LahD1 and D2, following linear azol(in)e-
containing peptides nomenclature (7), conspicuously lack cognate C proteins, which facilitate 
substrate recognition through the leader peptide (6, 14). Instead, LahD1 and D2 are reminiscent 
of the stand-alone YcaO proteins involved in bottromycin biosynthesis, and indeed bottromycin 
YcaO proteins are among the BLAST results with LahD1 and D2 as queries. Mutagenesis and 
metabolomics studies present evidence that the bottromycin YcaO proteins are responsible for 
cyclodehydrating and macrocyclizing the substrate (15). Unfortunately, absence of detailed in 
vitro characterization of these enzymes prevented assignment of the exact function of LahD1 and 
D2. 
As in the case of the multi-substrate Proc and Flv systems discussed in Chapter 2, the 
putative LanA peptides (LahA1-7) are encoded within proximity of the LanM and YcaO 
encoding genes (Figure 4.1A). In addition, there are two additional putative LanA peptides 
encoded on a different scaffold in the draft genome and not within a clear RiPP biosynthetic 
context (LahA8 and 9), which can be uncovered from subjecting the leader peptide to BLAST. 
The leader peptides of all nine LahA peptides are conserved and bioinformatically annotated as 
Nif11 (Figure 4.1C). The conservation of the LahA leader peptides contrasts with the core 
peptides, which exhibit limited similarity and several distinctly lack Cys residues (Figure 4.1B). 
The general lack of Cys residues, and presence of only one Cys in LahA4 and three each in 
LahA7 and A9, is perhaps correlated with the Zn-ligand deficient cyclization domains of the 
LahM proteins (Figure 4.2B). Despite few Cys residues, the LahA core peptides contain a fair 
number of Ser and Thr residues (Figure 4.1B). Although it is not readily discernable which 
residues would be cyclodehydrated versus dehydrated. 
Species from the genus Lachnospiraceae are anaerobic, Gram-positive isolates of 
disease-free mammalian digestive fauna (16-18). However, members of the genus are also 
implicated in the development of host disease states such as type 2 diabetes (19, 20) and 
resistance to Clostridium difficile colonization and thus infection (21). Both studies employed 
animal models, but did not present molecular deductions for the observed phenomena. Although 
a role of the Lah peptide products in mediating host disease or immunity is unclear, their 
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predicted modifications make them deserving candidates for biochemical characterization. 
Particularly intriguing aspects of the Lah system include: the division of biosynthetic labor 
coordinated by the suite of RiPP synthases, the biosynthetic order of post-translational 
modification events, the substrate tolerance implied by the multiple LahA peptides, the intra-
substrate site specificity of the post-translational modification enzymes, and the final structures 
of the compounds. Investigation of these aspects required reconstitution of the activity the Lah 
enzymes and determination of substrate modification. 
 
4.2.2 LahM proteins are active in the absence of other Lah enzymes 
 Initial exploration of the reconstitution of Lah enzyme activity focused on the arbitrarily 
chosen substrates LahA1 and A5 (Figure 4.1B and C). Co-expression of lahA1 with either lahM1 
or M2 resulted in a mass corresponding to unmodified peptide (Figure 4.3A). In contrast, co-
expression of lahA5 with lahM1 resulted in three-fold dehydrated peptide and mono and di-
phosphorylated peptide when co-expressed with lahM2 (Figure 4.3B). Due to the observed 
modifications, subsequent efforts were directed to the LahA5 substrate.  
 
Figure 4.3. LahA5 is modified by both LahM1 and M2. (A) LahA1 co-expressed with either LahM1 or M2 is not 
modified, calculated average [M+H]
+
 mass: 12573.6 m/z, observed average mass: 12574.3 m/z. (B) The spectrum 
for unmodified LahA5 is shown in black, calculated average [M+H]
+
 mass: 12760.1 m/z, observed average mass: 
12757.3 m/z. LahA5 co-expressed with LahM1, shown in blue, results in 3-fold dehydrated peptide, calculated 
average [M+H]
+
 mass: 12706.1 m/z, observed average mass: 12702.9 m/z.  LahA5 co-expressed with LahM2 is 
phosphorylated, diphosphorylated calculated average [M+H]
+
 mass: 12920.1 m/z, observed average mass: 12915.7. 
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Next, co-expression studies of lahA5 with binary combinations of the lahM or lahD1 proteins did 
not yield additional modification beyond that observed in the co-expressions with just the LanM 
enzymes. The partial modification of LahA5 presented the possibility that the chosen substrate 
did not undergo cyclodehydration or that poor expression of the proteins was inhibiting activity. 
In order to investigate the latter possibility, production and purification of the LahM enzymes 
was undertaken. 
The expression of the LahM proteins was first examined using His6-tagged enzyme. 
Unfortunately, attempts to purify either His6-LahM1 or M2 were hampered by low expression of 
the proteins, which was not remediated by the inclusion of rare tRNAs (22) or the molecular 
chaperones GroEL and ES (23) (Figure 4.4). However, expression and purification of a codon 
optimized, His6-maltose-binding protein fusion of LahM2 (His6-MBP-LahM2) was successful 
(24, 25). Correspondingly, His6-MBP-LahM1 (without codon optimization) could also be 
purified. In vitro assays of LahA5 with either His6-MBP-LahM1 or M2 resulted in the same 
modification extent as that observed in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Discussion 
 Several hypotheses can be presented regarding the biosynthetic order of the Lah system, 
first as in the case of the thiomuracin system, cyclodehydration must precede lanthipeptide 
synthase activity. Alternatively, the action of the lanthipeptide synthases occurs before the YcaO 
proteins or lastly the LahD and M enzymes function in tandem. The activity of the LahM 
Figure 4.4. MBP improves LahM2 expression. The expected band size is indicated by the arrowhead. 
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proteins observed for LahA5 is consistent with the latter two hypotheses (Figure 4.3B). 
Phosphorylation of LahA5 by M2 is perhaps not surprising given that the CylM Thr512 residue 
involved in phosphate elimination is a Pro390 in LahM2 and mutation of CylM Thr512 into Ala 
results in phosphorylated CylLS peptide (10), but it is unclear whether phosphorylation 
represents a modification in the LahA5 final product. However, the data do not exclude the 
possibility that the observed modification of LahA5 by LahM1 and M2 is incomplete and full 
modification requires a YcaO-generated intermediate of LahA5. The observed inactivity of 
LahD1 renders determination of its biosynthetic role and regioselectivity difficult. Future co-
expression and in vitro studies employing both LahM1 and M2 will clarify the possibility of the 
enzymes functioning in tandem to affect modification. Due to the successful preparation of 
MBP-LahM2 and in vitro reconstitution, the purification of MBP fusions of the remaining Lah 
proteins is underway. 
 Given the similarity of the LahA leader peptides (Figure 4.1C) it is perhaps not surprising 
that the Lah proteins do not discern between discrete sets of substrates, as in the case of two-
component lantibiotic systems (26). However, it seems impressive that each LahA substrate 
would require the activity of four to five enzymes for structural maturation. In addition, the six 
amino acid difference in length between the LahA1-5 and LahA6-9 peptides suggests leader 
peptide-mediated positioning of the substrate within the LahD or M active sites (27-29). These 
observations could argue against necessitating both LanM proteins for the modification of each 
substrate. Lastly, the absence of modification for LahA1 when co-expressed with either LahM1, 
M2 or D1 (Figure 4.3A) could be explained by LahM substrate discrimination being determined 
by preceding modification of the substrate by the LahD protein(s), which cannot be completely 
ruled out for this substrate. 
 
4.4 Materials and methods 
4.4.1 Culturing Lachnospiraceae C6A11 and gDNA isolation 
Anaerobic culture of L. C6A11 was performed as described for Ruminococcus 
flavefaceins FD-1 in chapter 2, with modifications noted. The growth rate of L. C6A11 is slow, 
requiring ~7 d before reaching early lag phase. Thus, liquid and solid cultures were allowed to 
incubate for a minimum of 4 d at 37 °C before assessment by microscope. Furthermore, after 
liquid media was injected into agar slants, the slant was incubated for two-three d before transfer 
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to fresh liquid media. Initially, liquid RM02 and agar L. C6A11 slants were kindly provided by 
Dr. William Kelly’s lab in AgResearch Limited in New Zealand and the liquid cultures were 
simply transferred to fresh media and allowed to incubate for 4-5 d. Upon establishment of an 
active L. C6A11 culture, gDNA was isolated using a MoBio kit, as per the manufacturer’s 
instructions. L. C6A11 growth in the liquid media used to culture R. flavefaciens FD-1 in chapter 
2 (approximately the same time scale as the R2YE media) was observed. Growth in agar slants 
of R. flavefaciens FD-1 media inoculated with L. C6A11 was also observed, thus agar slants of L. 
C6A11 were prepared using the same media for R. flavefaciens FD-1 agar slants described in 
chapter 2. 
 
4.4.2 Cloning, expression, purification, and analysis of Lah peptides 
See Chapter 2 for detailed descriptions, and any modifications are noted. Rather than 
using ligation reactions, Gibson assembly was used to assemble all plasmids (30). In preparation 
for Gibson assembly, backbone plasmid DNA was linearized using restriction endonucleases 
followed by treatment with CIP and purification using a QIAquick Gel Extraction Kit. Insert 
DNA obtained by PCR amplification was also purified using a QIAquick Gel Extraction Kit. In 
preparation for Gibson assembly, 5× Isothermal Reaction Buffer was prepared by dissolving 1.5 
g PEG-8000 in 3 mL of 1 M Tris-HCl pH 7.5 with incubation in a 55 °C water bath, this solution 
was allowed to cool to room temperature before adding the remaining reagents (150 µL 2 M 
MgCl2, 60 µL of 100 mM dGTP, 60 µL of 100 mM dCTP, 60 µL of 100 mM dATP, 60 µL of 
100 mM dTTP, 300 µL of 1M DTT, 300 µL of 100 mM NAD
+
, and water to a final volume of 6 
mL). Then the Gibson assembly reaction mixture was prepared by combining 320 µL of 5× 
Isothermal Reaction Buffer, 860 µL of sterile water, 0.64 µL of T5 Exonuclease, and 20 µL of 
Phusion Polymerase. Then, 15 µL of the Gibson assembly reaction mixture was combined with 
50-100 ng of backbone DNA and a 30-50 fold excess (normalized to ng/kb) of insert DNA. The 
Gibson assembly reactions were incubated at 50 °C for 1 h and then used to transformed 
chemically competent E. coli DH10B (or plasmid maintenance cell line). Since a variety of 
plasmid backbones were used, the final backbone is noted in the primer table for each set of 
primers. A table of the prepared constructs and a brief description is also provided. 
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Table 4.1. Primers for cloning lah genes. 
Primer sequence 5′ to 3′ Annealing 
temperature, °C 
Primer direction, construct 
name_plasmid backbone 
gtataagaaggagatatacatATGAAGCAGAATGAATTCTA
CGATTATATATC 
60 Forward, LahM1_mcs2_pACYC 
gcagcggtttctttaccagactcgagTCATGTTAATTCCTCCTT
AGTTTTTTTTATTG 
60 Reverse, LahM1_mcs2_pACYC 
gttaagtataagaaggagatatacatATGAACTTAACACTGAA
GCAATGGCTGG 
60 Forward, LahM2_mcs2_pACYC 
gcagcagcggtttctttaccagactcgagCTACTTCGACAGCCA
TCCCAAAAATAAAAC 
60 Reverse, LahM2_mcs2_pACYC 
gtatattagttaagtataagaaggagatatacatatgAAAATCGAAGA
AGGTAAACTG 
62 Forward, MBP-
LahYcao1_mcs2_pCDF1 
GGTGTTCTGTCCTTATATTTTGAATAATTACTCT
CGAGGGATCCGGATTG 
62 Reverse, MBP-
LahYcao1_mcs2_pCDF1 
CAATCCGGATCCCTCGAGAGTAATTATTCAAAA
TATAAGGACAGAACACC 
62 Forward, MBP-
LahYcao1_mcs2_pCDF1 
gcagcggtttctttaccagactcgagTTAATATTCTCTGCCGTA
TATTTCCTTTAATTC 
62 Reverse, MBP-
LahYcao1_mcs2_pCDF1 
cctggtgccgcgcggcagccatatgAAGCAGAATGAATTCTA
CGATTATATATCCG 
67 Forward, His6-LahM1_pET15b 
gctttgttagcagccggatccTCATGTTAATTCCTCCTTAGT
TTTTTTTATTGC 
67 Reverse, His6-LahM1_pET15b 
gcagcggcctggtgccgcgcggcagccatatgAACTTAACACTG
AAGCAATGGCTGGAG 
67 Forward, His6-LahM2_pET15b 
cctttcgggctttgttagcagccggatccCTACTTCGACAGCCAT
CCCAAAAATAAAAC 
67 Reverse, His6-LahM2_pET15b 
catcacagcagcggcctggtgccgcgcggcagccatAAAATCGAA
GAAGGTAAACTG 
62 Forward, His6-MBP-
LahM2_codon 
optimized_pET15b 
CTTCAAACAGTTCCAGCCATTGCTTCAGGGTCA
GGTTAGTCTGCGCGTCTTTCAGG 
62 Reverse, His6-MBP-
LahM2_codon 
optimized_pET15b 
CAGACTGTCGATGAAGCCCTGAAAGACGCGCA
GACTAACCTGACCCTGAAGCAATGG 
62 Forward, His6-MBP-
LahM2_codon 
optimized_pET15b 
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Table 4.1. (cont.) 
ctcagcttcctttcgggctttgttagcagccggatccTTACTTGCTCA
GCCAGCCC 
62 Reverse, His6-MBP-
LahM2_codon 
optimized_pET15b 
Primers for the substrates were designed by Dr. Huo. 
 
Table 4.2. Application of selected Lah constructs. 
Construct Comments 
His6-LahA_mcs1_pRSF For (co-)expression and purification 
LahM1_mcs2_pACYC For co-expression with lahA genes 
LahM2_mcs2_pACYC For co-expression with lahA genes 
MBP-LahYcao1_mcs2_pCDF1 For co-expression with lahA genes 
His6-LahM1_pET15b For purification and in vitro studies 
His6-LahM2_pET15b For purification and in vitro studies 
His6-MBP-LahM2_codon optimized_pET15b For purification and in vitro studies 
 
 Small scale pilot expressions of the lahA peptide genes were carried out prior to larger 
expressions. In these cases, a single colony transformant was inoculated into 30 mL of liquid LB 
culture containing the appropriate antibiotic(s). The culture was incubated with shaking at 37 °C 
until an OD600 of 0.6-0.8 was achieved at which point IPTG was added to a final concentration of 
50 µM. The culture was then incubated with shaking at 18 °C for 18-20 h and then harvested and 
stored until lysis. Larger expressions were carried out as described in Chapter 2 but with a post-
induction temperature of 18 °C rather than 37 °C since primarily unmodified LahA5 peptide was 
observed from co-expressions employing a 37 °C post-induction temperature. 
 
4.4.3 Expression and purification of Lah proteins 
 Expressions were carried out as described in Chapter 2 but with a post-induction 
temperature of 18 °C rather than 37 °C. Protein purifications were carried out as previously 
described for LanM proteins (31) with the following modifications. The cell pellet was lysed 
using an Avestin EmulsiFlex-C3, and an Äkta FPLC was used to elute the protein during IMAC. 
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Chapter 5. Investigations into the sLanB-encoding gene cluster of Bacillus halodurans C-
125
*
 
 
5.1 Introduction 
In vitro reconstitution of the full length LanB enzyme, NisB, which is involved in the 
biosynthesis of the lantibiotic nisin, provided unprecedented insight into the mechanism of LanB 
enzymes (1). NisB was demonstrated to add a glutamyl group, derived from aminoacylated-
tRNA
Glu
, to the Ser and Thr residues of the NisA precursor peptide and eliminate the glutamate 
to form Dha and Dhb. This mechanism diverges from that of the class II-IV synthetases 
discussed in Chapter 1. The insights gained from NisB provide a backdrop for understanding 
LanB-like enzymes encoded in non-lanthipeptide gene cluster contexts. Indeed, in vitro 
reconstitution and confirmed dependence on aminoacyl-tRNA (aa-tRNA) was forthcoming for 
the canonical class I synthase lantibiotic synthase MibB (2)  and the split LanB enzymes TbtB 
and C (discussed in further detail in Chapter 4) (3). Perhaps even more intriguing are the 
instances of LanB-like enzymes that lack a discernable elimination domain, which in NisB 
eliminates glutamate from the glutamylated intermediate to produce dehydrated substrate. 
Although bioinformatics was critical in identifying these sLanB enzymes (1), additional 
mechanistic and structural ramifications could not be deduced in the absence of more detailed 
investigations. Thus, a sLanB-containing gene cluster was identified and heterologous expression 
of the cluster as well as mechanistic investigation of one of the sLanB enzymes was attempted. 
 
5.2 Results 
5.2.1 The Hdn sLanB proteins bear hallmarks of LanB proteins 
The proposed hdn gene cluster in B. halodurans C-125 consists of 18 genes, seven of 
which encode for sLanB enzymes (Figure 5.1A). Although an N-terminal lanthipeptide 
dehydratase domain is annotated in some of the HdnB proteins, pFAM analysis also reveals a 
conspicuous absence of a C-terminal lanthipeptide dehydratase domain for all seven enzymes 
(Figure 5.1B). The annotated N-terminal lanthipeptide dehydratase domain corresponds to the 
                                                 
*
 Studies were done in collaboration with Dr. Rebecca Splain. Dr. Splain cloned the hdn genes, heterologously 
expressed and purified them, and conducted the in vitro assays. X. Zhao cloned portions of the hdn gene cluster and 
heterologously expressed the cloned gene cluster. X. Zhao also prepared the materials for and performed the 
phosphorus NMR studies. 
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glutamylation domain in the NisB crystal structure, which esterifies the Ser and Thr residues in 
the NisA precursor with glutamate from glutamyl-tRNA
Glu
 (1). Subsequently, the NisB 
elimination domain catalyzes the elimination of glutamate from NisA to yield dehydro amino 
acids. 
 
Figure 5.1. The hdn gene cluster encodes multiple sLanB proteins. (A) hdn gene cluster, with the HdnB proteins 
colored magenta and proteases colored green. The lines below the cluster denote portions that were cloned together 
for co-expression studies. The first portion of the cluster was altered such that a his6-hdnA gene was placed before 
the other genes in the hdn cluster while the endogenous hdnA was abolished (inset) (B) Domain architecture 
comparison of full length and sLanB proteins, showing the lack of elimination domain in HdnB3. (C) Amino acid 
sequence of HdnA and NisA. (D) Maps of the constructs used for the co-expression studies (also see Figure 5.3), 
primer sequences can be found in Section 5.4. Complementary constructs in which the first or second mcs was 
empty were also prepared. 
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Despite the presence of several sLanB enzymes in the hdn gene cluster, only a single gene 
encoding for a 39 amino acid peptide (HdnA) was detected in the cluster. Intriguingly, the 
residue composition of HdnA differs from that of prototypical LanB precursor peptides (Figure 
5.1C). Specifically, compared to NisA, HdnA is shorter in length, lacks any Ser, Thr, and Cys 
residues, and exhibits an abundance of Asp and Glu residues (17 out of 39 amino acids). In 
addition to the Hdn sLanB proteins, two Zn-dependent proteases (HdnP1 and 2) are annotated 
(Figure 5.1A), but their exact roles in biosynthesis were unclear. The profusion of and 
mechanistic implications of the sLanB enzymes in the hdn gene cluster presented an intriguing 
opportunity to extend the understanding of LanB-like enzymes. Thus, investigation of the 
enzymes and the resultant product of the hdn gene cluster was undertaken. 
 
5.2.2 sLanB enzymes add amino acids to the C-terminus of a substrate peptide 
All of the Hdn sLanB enzymes (1-7) were expressed as soluble His6 fusion proteins. In 
vitro assays of combining HdnA with E. coli cell extract, ATP, Mg
2+
, glutamate, and TCEP 
resulted in an increase in mass of the HdnA precursor peptide (Figure 5.2A). Subsequent in vitro 
assays with deuterated amino acids suggested that HdnB1 generated HdnA+Ala and HdnB7 
accepted this as a substrate to produce HdnA+AlaTrp (Figure 5.2B-D). These observations 
prompted investigation of whether the HdnB enzymes functioned within a heterologous host. 
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Figure 5.2. Addition of Ala and Trp to HdnA. In vitro assays using cell extract of (A) HdnA and B1, (B) HdnA+Ala 
and HdnB7, and (C, D) deuterated amino acids. Co-expressions of (E) His6-HdnA and B1 and (F) His6-HdnA, B1, 
and B7. 
 
 
5.2.3 Co-expression of the hdn genes 
Co-expression of hdnA and B1 yielded a peptide with a mass corresponding to the 
HdnA+Ala (Figure 5.2E). In addition, co-expressing the genes encoding for HdnA, B1 and B7, 
yielded a peptide mass corresponding to HdnA+AlaTrp (Figure 5.2F). Given the successful 
reconstitution of Hdn protein activity in E. coli, co-expressions encompassing additional portions 
of the hdn gene cluster were attempted (Figure 5.3 and see Figure 5.2A for gene cluster 
portions). However, co-expressing additional portions of the hdn gene cluster did not result in 
additional mass changes (Figure 5.3). 
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Figure 5.3. Co-expression of portions of the hdn gene cluster. Peaks with masses corresponding to unmodified 
HdnA peptide are labeled “M”. Portions of the gene cluster that were co-expressed are shown in detail in Figure 5.1. 
Co-expression of (A) the full hdn gene cluster, (B) the first, second, and fourth portions of hdn gene cluster without 
hdnP1 and P2, (C) the first two portions of hdn gene cluster without hdnP1 and P2, (D) the hdn gene cluster without  
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Figure 5.3. (cont.) 
hdnP1 and P2, and (E) second and fourth portions of hdn gene cluster with hdnA. * denotes a mass corresponding to 
gluconoylated peptide. Spectra were acquired from samples that were subjected to IMAC. 
 
 
5.2.4 Mechanistic investigations of HdnB7 
Inspired by the mechanistic investigations of other RiPP enzymes, analogous studies 
were undertaken for HdnB7 (4, 5). First, the dependence of HdnB1 on ATP was evaluated by 
supplying aa-tRNA in the absence of ATP. However, addition of Ala to HdnA was not observed 
until ATP was also included. This suggested that ATP was used to activate the carboxylate of 
HdnA, and it was envisioned that incorporation of isotopically labelled Ala into the C-terminus 
of the HdnA peptide would provide a handle that could inform on the mechanism of catalysis.  
 
Figure 5.4. Two proposed mechanisms of catalysis for HdnB7, the C-terminal 
18
O isotope label in HdnA 
(incorporated using HdnB1) is colored red. 
 
 
Ala bearing doubly labelled oxygen-18 (Ala-
18
O2) at its carboxylate was selected for its minimal 
perturbation to the substrate, and phosphorus-31 nuclear magnetic resonance spectroscopy (
31
P 
NMR) was selected by precedent (6). Two mechanisms (Figure 5.4) were proposed, operation of 
the first mechanism, which proceeds through a phosphopeptide intermediate, would result in the 
production of a 50:50 mixture of 
18
OPO3
3−
 and PO4
3−
 under both single- and multiple turnover 
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conditions. In contrast the second proposed mechanism would yield exclusively
 18
OPO3
3−
 under 
single-turnover conditions (limiting peptide) and a mixture of 
18
OPO3
3−
 and PO4
3−
 under multiple 
turnover conditions. Although a single phosphate peak was observed under single-turnover 
conditions, a single phosphate peak was also observed under multiple turnover conditions of 
HdnB7, rendering substantiation of either mechanism difficult. 
 
5.3 Discussion 
Despite an increasing appreciation for the ubiquity of aa-tRNA-dependent enzymes 
involved in secondary metabolism (7, 8), few share annotated sequence similarities with the 
HdnB enzymes. However, an analogous biosynthetic gene cluster was highlighted in recent work 
by the Moore lab on the biosynthesis of pyrroloquinoline alkaloids from the marine bacterium 
Streptomyces sp. CNR-698 (9). Production of the small molecule ammosamide was abolished 
upon deleting genes within the amm gene cluster, which shares features with the hdn cluster. 
Specifically, the amm gene cluster from S. sp. CNR-698 features four annotated sLanB proteins 
as well as an acidic precursor peptide (encoded by amm6) that exhibits conservation with the C-
terminus of HdnA. Unfortunately, the in vitro activity of the Amm sLanB proteins was not 
reconstituted, and thus their role in ammosamide biosynthesis remains unclear. Based on the 
findings of the Moore lab, it is tempting to speculate that a similar underlying biosynthetic logic 
is operative in the Hdn system, in which a ribosomally-encoded peptide is the biosynthetic origin 
of a small molecule final product. However, it cannot be excluded that the precursor peptide of 
the Amm system is tailored into a final product that regulates the production of ammosamides. 
The observation of primarily unmodified HdnA upon expression of portions of the Hdn 
gene cluster is puzzling (Figure 5.3). However, this observation could be consistent with a model 
in which HdnA serves as a scaffold that is modified, proteolyzed, and regenerated (possibly by 
the sLanB proteins). Alternatively, lack of further HdnA peptide modification could be the result 
of unsuccessful enzyme expression in E. coli. Indeed, attempts to purify either His6-HdnP 
protease resulted in insoluble protein. The current heterologous host may be a less than ideal 
platform for the expression of the hdn gene cluster, thus hampering full pathway reconstitution. 
Alternative approaches to circumvent host incompatibility could include genetic manipulation of 
B. halodurans C-125 or introduction of the Hdn gene cluster into a Bacillus heterologous host. 
The primacy of the former approach is evidenced by the studies on the ammosamides. 
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The lack of discrete 
18
OPO3
3−
 and PO4
3−
 peaks in the 
31
P NMR spectrum of the HdnB7 
reaction can be attributed to insufficient resolution or production of phosphate that is not coupled 
to substrate turnover. The latter possibility is more likely since control studies in which 
18
OPO3
3−
 
and PO4
3−
 was generated and prepared by 17x-PTDH and added to the HdnB7 in vitro assay 
sample buffer (see Section 5.4 for more details) yielded clearly distinct 
18
OPO3
3−
 and PO4
3−
 
peaks. Furthermore, the possibility of 
18
OPO3
3−
 signal suppression by PO4
3−
 contamination was 
excluded by monitoring for the potential presence of PO4
3−
 in the individual components of the 
HdnB7 in vitro reaction. No PO4
3−
 contamination was observed if the tRNA was purified by 
denaturing, acidic polyacrylamide gel as previously described for aa-tRNA (10). However, the 
production of phosphate by HdnB7 was not monitored using 
31
P NMR in the absence of full 
length HdnA peptide nor in the presence of HdnA leader peptide. It is anticipated that in both of 
these cases the production of a nontrivial amount of phosphate would be observed. Future 
attempts to examine the mechanistic details of sLanB enzymes should be preceded by evaluation 
of ATP-hydrolysis activity under various conditions, prior to generation of isotopically labelled 
substrate. Phosphate production should be examined in absence of both the peptide substrate and 
aa-tRNA, the presence of peptide substrate and absence of aa-tRNA, and vice versa. 
 
5.4 Materials and methods 
5.4.1 General materials and methods 
 Reagents were the same as those specified in Chapter 2. Sodium phosphate monobasic, 
monohydrate was purchased from Fischer Scientific and adenosine di- and triphosphate hydrates 
were purchased from Sigma-Aldrich. 
 
5.4.2 Culturing B. halodurans C-125 and gDNA isolation 
All procedures were performed aseptically. B. halodurans was maintained as a 40% 
glycerol stock at −80 °C. The glycerol stock was revived by first streaking onto solid LB media 
and incubating at 37 °C for 16-20 h. A single colony of the organism was transferred into 5 mL 
of liquid LB media and incubated at 37 °C, 200-220 rpm for ~24 h. gDNA was isolated using a 
MoBio kit, as per the manufacturer’s instructions. 
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5.4.3 Cloning, expression, and analysis of the hdn gene cluster 
See Chapter 2 for detailed descriptions, and any modifications are noted in Chapter 4. 
Specifically, Gibson Assembly was used to assemble all plasmids (11). Single restriction 
endonuclease digestion of the hdn gene cluster constructs indicated incorporation of inserts of 
the correct size, and sequencing of the 5’ and 3’ extremities of each mcs also indicated the 
expected insert sequences. However, full sequencing coverage of each portion of the hdn cluster 
was not achieved (a typical sequencing run provided ~1 kb of data), and full sequencing 
coverage is necessary to rule out the unlikely possibility of point mutations in the constructs. The 
HdnA-bearing construct was designed such that a his6-hdnA gene was placed before the 
remaining genes in the hdn cluster and the endogenous copy of hdnA was removed (inset). 
 
Figure 5.5. hdn gene cluster key for cloning. 
 
 
Table 5.1. Primers for cloning hdn genes. 
Primer sequence 5′ to 3′ Annealing 
temperature, °C 
Primer direction, construct 
name_ plasmid backbone_ 
restriction site/ overlap sequence 
gcagcagccatcaccatcatcaccacagccaggatccaATGGCCGAC
AAGGTTACACC 
66 Forward, 
HisBh35_mcs1_pACYC_ 
BamHI 
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Table 5.1. (cont.) 
ggcgcgccgagctcgaattcTTAAAGAGCCAGAGGAGCGA
C 
66 Reverse, HisBh35_ 
mcs1_pACYC_ plasmid overlap 
CCTCTGGCTCTTTAAggcgcgccaggagatataccATGTTA
TCCGAACGAACAAAACTAG 
63 Forward, Bh33,34 overlap35_ 
mcs1_pACYC_ AscI 
CAAAAATATGCAAGTTTTGCATttcaagttccccttTTA
ACCCATGAGCATATCTTTGG 
63 Reverse, Bh33,34 overlap36_ 
mcs1_pACYC_ Bh36 overlap 
GCAGACTCATTGATTATTTTCATagtccacctcttTTAA
CCCATGAGCATATCTTTGG 
62 Forward, Bh38_ mcs1_pACYC_ 
Bh34 overlap 
GATATGCTCATGGGTTAAaagaggtggactATGAAAA
TAATCAATGAGTCTGCAC 
62 Reverse, Bh33,34_ 
mcs1_pACYC_ Bh38 overlap 
GCAAGAGATAACTTCCAAAGATATGCTCATGGG
TTAAaaggggaacttgaaATGCAAAAC 
64 Forward, 
Bh36,7,8_mcs1_pACYC_ Bh34 
overlap 
ctgttcgacttaagcattatgcggccgcCTAAAACCAAAGCTTA
TGAAAAGGGTAG 
64 Reverse, 
Bh36,7,8_mcs1_pACYC_ NotI 
caccacagccaggatccgaattcgagctcggcgcgccacATGCCAAC
ATCGAAACTTG 
60 Forward, Bh43,44_mcs1_pET1_ 
AscI 
CTAGATTGTTTCACTGACAACATCACCTTCTAAC
TTTTTCATAAATGTC 
60 Reverse, Bh43,44_ mcs1_pET1_ 
Bh45 overlap 
ATTGGGGATTAAGGAGGTTTCTGAACATGCGTG
AATTTCCAACAATTG 
66 Forward, Bh45,46_ mcs1_pET1_ 
Bh44 overlap 
ctttctgttcgacttaagcattatgcggccgcTTAAATATTAGCTTG
AAGCGTTTCTTGC 
66 Reverse, Bh45,46_ mcs1_pET1_ 
NotI 
gttaagtataagaaggagatatacatatgATGATCATTAGCATTT
CAAATCTCTCAC 
65 Forward, Bh47-50_mcs2_pET1_ 
NdeI 
gcagcagcggtttctttaccagactcgagTTATTTGCTTTGATAT
CGTAACGAGATTTC 
65 Reverse, Bh47-50_ mcs2_pET1_ 
XhoI 
AATTCCTGCAGTAATACGACTCACTATAGGGGC
TATAGCTCAGCTGGGAGAGCGC 
 tRNA
Ala
_F 
mUmGGTGGAGCTATGCGGGATCGAACCGCAGA
CCTCCTGCGTGCAAAGCAGGCGCTCTCCC 
 tRNA
Ala
TGC_R 
AATTCCTGCAGTAATACGACTCACTATAAGGGG
CGTAGTTCAATTGGTAGAGCACCG 
 tRNA
Trp
_F 
mUmGGCAGGGGCGGAGAGACTCGAACTCCCAA
CACCCGGTTTTGGAGACCGGTGCTCTA 
 tRNA
Trp
_R 
m stands for  2'-O-methyl sugar 
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 Small scale expressions of portions of the hdn gene cluster were carried out as described 
in Chapter 4. Larger expressions were carried out as described in Chapter 2 but with a post-
induction temperature of 18 °C rather than 37 °C. 
 
5.4.4 Expression and purification of sLanB proteins 
 Expressions and purifications were carried out as described in Chapter 2 for LanM 
proteins (12), with the following modifications. HdnB Lysis Buffer (20 mM Tris, pH 7.6, 500 
mM NaCl, 10% glycerol), HdnB Elution Buffer (20 mM Tris, pH 7.6, 500 mM NaCl, 500 mM 
imidizole, 10% glycerol), HdnB SEC Buffer (20 mM HEPES, pH 7.5, 600 mM KCl, 10% 
glycerol). Rather than PD‐10 size exclusion chromatography, all proteins were loaded onto a 
Superdex-200 gel filtration column equilibrated with SEC Buffer in order to minimize the 
phosphate contamination. Proteins were concentrated using an Amicon centrifugal filter with a 
30 kDa nominal molecular weight limit (NMWL, EMD Millipore). 
 
5.4.5 In vitro transcription and purification of tRNA 
 E. coli tRNA and aminoacyl-tRNA synthetase (aaRS) were used since full conversion of 
HdnA by HdnB1 and HdnA+Ala by HdnB7 was observed using these co-factors. Preparation of 
tRNA was performed as previously and briefly described below (1). In order to ensure good 
yield, all buffers were freshly prepared (using RNase free or autoclaved water) for the generation 
of template DNA or the in vitro transcription reactions. First, double-stranded template DNA 
was generated by incubating final concentrations of 1× NEB Buffer 2, 4 μM of each primer (see 
above primer table), 33 μM of dNTPs, and 1 U/μg of DNA of NEB DNA pol I (large Klenow 
fragment) in a final volume of 50 μL. Several reactions (rather than larger volume reactions) 
were setup to obtain sufficient quantities of double-stranded DNA. Reactions were incubated at 
25 °C for 15-30 min before being quenched with EDTA (10 mM final concentration) and heating 
at 75 °C for 20 min. The resulting DNA was precipitated using ethanol (2 volumes of pre-chilled 
ethanol was added and the sample was incubated at −20 °C for 30-180 min), dried using 
nitrogen, redissolved in water, and used in transcription reactions. Transcription reactions were 
setup according to a previously described method (13). The resulting tRNA was purified by 
acidic phenol extraction (for tRNA precipitation, 2.5 volumes of pre-chilled ethanol was added 
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and the sample was incubated at −20 °C for 1 h) and denaturing, acidic polyacrylamide gel as 
previously described for aa-tRNA (10). Concentration of tRNA was achieved by using a 10 kDa 
NMWL Amicon centrifugal filter according to the manufacturer’s instructions. 
 
5.4.6 In vitro sLanB reactions and preparation of 
31
P NMR samples 
In vitro sLanB reactions consisted of final concentrations of 200 mM HEPES, pH 7.6, 1 
mM ATP, 10 mM MgCl2, 100 mM KCl, 8 µM amino acid, 6 µM tRNA, 1 µM aaRS, 20 µM 
peptide, and 8 µM HdnB enzyme. The inclusion of amino acid, tRNA, and aa-RS, allowed for in 
situ aminoacylation due concerns regarding the generation and purificaiton of sufficient amounts 
of aa-tRNA. In order to produce sufficient quantities of HdnA+Ala-
18
O and 
18
OPO3
3−
 (for 
detection by NMR), HdnB reactions were run on a 1-2 mL scale. Isotopically labelled 
HdnA+Ala-
18
O was prepared using the same in vitro reaction conditions, except Ala was 
substituted with Ala-
18
O2. The progress of the in vitro reactions was analyzed by subjecting the 
sample to Zip-Tip and MALDI-TOF-MS (details in Chapter 2, Section 2.4). Full conversion of 
HdnA to HdnA+Ala was observed after 15 min, thus, reactions were allowed to incubate for 30-
60 min at 25 °C. After confirming full conversion to HdnA+Ala-
18
O, the isotopically labelled 
peptide was isolated from the reaction mixture using analytical scale RP-HPLC (described in 
Chapter 2, Section 2.4). 
The HdnB7 in vitro reactions were setup and monitored in the same way described for 
the HdnB1 reactions. However, after incubation, the sample was passed through a 0.5 mL 
Amicon centrifugal filter with a 10 kDa NMWL to remove the proteinaceous components, and 
the reservoir was rinsed with two additions of 100 µL of water. The total flow-through was flash 
frozen and dried to completion in vacuo. The solid was re-dissolved in 150-180 µL of D2O and 
insoluble components were removed by centrifugation. The resulting supernatant was transferred 
into a 3-5 mm NMR tube. A 600 MHz Agilent NMR maintained by the Carl R. Woese Institute 
for Genomic Biology at UIUC was used to acquire spectra. Data was acquired using VnmrJ and 
analyzed using MestReNova. The identity of phosphate-containing components (e.g. ATP, ADP) 
was confirmed by spiking using stock solutions to a final concentration of 0.2-1 mM. 
17X-PTDH was used to generate 
18
OPO3
3−
 and PO4
3−
 by incorporating H2O
18
 into 
reactions based on previous conditions (14) and described as follows. The following components 
were combined to a final volume of 500 µL and incubated at 25 °C for 2.5 h (100 mM MOPS, 
114 
 
pH 7.25, 3.77 mM NAD
+
, 1 mM HPO3
3−
, 2 µM 17X-PTDH, 27 µL of H2O
18
 , and 46 µL of 
H2O). After preparation and sample analysis as described in the preceding paragraph, a doublet 
was observed at 2.5 p.p.m (~2.78 mM total phosphate). Dilution of the sample (~10-fold) 
resulted in loss of resolution and signal. Phosphate contamination was observed in tRNA that 
had been not been subjected to PAGE purification. 
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